

Rethinking

**A CASE FOR HUMILITY,
PRECISION, AND
PARENTAL PARTNERSHIP**

 **Independent**Women®



Independent Women is a 501(c)(3)
nonprofit organization advancing policies
that actually enhance opportunity and well-being.

Rethinking **VACCINE POLICY**

**A CASE FOR HUMILITY,
PRECISION, AND
PARENTAL PARTNERSHIP**

BY DR. MONIQUE YOHANAN, MD, MPH

 **IndependentWomen®**

TABLE OF CONTENTS

Executive Summary.....	1
The American Exception: A System Under Strain	3
Childhood Immunity: A Biological and Developmental Perspective.....	9
Herd Immunity: Essential, but Not Applicable for All Vaccines	13
Historical Legal Context: Jacobson and the Evolution of Vaccine Authority	19
The Perfect Storm of the 1980s: A Decade That Shaped Modern Vaccine Policy.....	27
Evidence Gaps and Misapplied Standards	35
The Information Revolution and Parental Decision-Making	45
A Path Forward: Aligning Science, Biology, and Public Trust.....	49
Conclusion.....	55
About the Author	56
Endnotes	57

EXECUTIVE SUMMARY

Vaccines represent one of medicine's most important tools for preventing disease and have contributed significantly to public health over the past century.¹ Despite these successes, our approach to vaccine policy has evolved in ways that have undermined both public trust and optimal health outcomes. This paper does not question the value of vaccination as a public health strategy. It examines how current policies, practices, and messaging may be counterproductive to achieving the highest levels of protection against truly threatening communicable diseases.

Polarization rarely leads to optimal outcomes, particularly in areas as important as child health. This examination seeks to identify a more balanced path forward that respects both public health imperatives and individual autonomy, a path grounded in evidence, international experience, and honest acknowledgment of where American policies have exceeded their original scope and justification.

When vaccine mandates are considered, this decision must be evaluated with clarity, humility, and proportionality. Not all vaccines serve the same public health function. Some prevent highly contagious and dangerous diseases where individual choice directly affects the safety of others—these may warrant stronger societal expectations and, in some cases, may appropriately include requirements. Others, however, primarily offer individual protection against diseases that are not casually spread or are extremely rare in childhood. In those cases, sweeping mandates—especially those tied to school access—can do more harm than good, undermining trust without delivering meaningful public health gains.

A thoughtful vaccine policy must distinguish between these categories and be grounded in a transparent framework that considers communicability, disease severity, timing of exposure, immune system development, and the effectiveness of the intervention. It must also account for the societal consequences of enforcement. In the United States, where mandates are most often tied to public

school attendance, the unintended consequences of exclusion—educational disruption, social isolation, and mental health decline—can themselves become public health problems. The experience of prolonged school closures during the COVID-19 pandemic is a sobering reminder of the broader harms that can result from blunt public health tools.

This paper calls for a recalibration: One that protects the public from serious threats without overreaching in ways that fracture trust or deny children access to essential aspects of society. It advocates for a policy grounded not just in the availability of vaccines, but in the nature of the diseases they target, their effectiveness in protecting others, and the broader consequences mandates may carry.

THE AMERICAN EXCEPTION: A SYSTEM UNDER STRAIN


The crisis in American vaccination policy manifests most starkly in the numbers: In July 2024, 38 states reported measles cases, indicating a breakdown in the 95% vaccination rate necessary for herd immunity.² Research later that year confirmed this concern, finding measles vaccination rates had fallen to 92.7% nationally, while vaccine exemptions reached a record high of 3.3%—with some jurisdictions exceeding 12%.³ An estimated 13% or more of children are described as under-vaccinated because of parental choice, with studies showing 9-13% following alternative vaccination schedules, and potentially eroding coverage rates necessary for essential vaccines.⁴

These statistics reveal a deeper truth: Parents are not simply rejecting vaccination wholesale but making increasingly sophisticated decisions about which vaccines to accept, when to accept them, and under what circumstances. This selective approach reflects a growing recognition that different vaccines serve different purposes, even as our policies continue to treat them as equivalent community obligations.

The United States has constructed one of the world's most comprehensive—and most front-loaded—childhood vaccination programs, yet paradoxically faces a breakdown in the very consensus needed to maintain protection against diseases that should be entirely preventable.⁵

THE UNPRECEDENTED EXPANSION OF THE AMERICAN SCHEDULE

To understand how we arrived at this crossroads, we need to examine the dramatic transformation of American childhood vaccination. The scope of this change is rarely comprehensively acknowledged, yet it represents one of the most significant shifts in pediatric healthcare since the mid-20th century.



The evolution of the U.S. vaccine schedule tells a story of remarkable expansion.⁶ The development of this schedule reflects both medical advances and policy decisions that concentrated immunological interventions in early childhood.⁷

This represents more than a doubling of the antigens children receive compared to the pre-1980s era, with an unprecedented concentration of vaccines in early childhood. Modern American children receive as many as 27 shots by two years of age, with up to six shots in a single visit.⁸ The majority of the total number of immunizations that will be administered are completed by a child's second birthday, with additional doses required prior to kindergarten entry at ages four to six.⁹

FROM RECOMMENDATIONS TO MANDATES

In America, we maintain the polite fiction that our vaccine schedule consists of “recommendations,” not requirements. The Centers for Disease Control and Prevention’s (CDC) color-coded charts come emblazoned with the word “Recommended,” suggesting flexibility and choice. Yet for most families, this distinction exists only on paper. In practice, these recommendations function as mandates, enforced through a sophisticated architecture of institutional pressure points that transform medical suggestions into practical necessities.

The journey from recommendation to mandate follows a predictable path. When the CDC Advisory Committee decides to add a vaccine to the childhood schedule, it triggers a cascade of consequences: Recommendations are added to insurance company coverage requirements, state legislatures incorporate these recommendations into school entry requirements; school districts demand compliance through enrollment forms; pediatric practices implement protocols flagging any deviation as “non-compliance”; and parents discover that declining even a single recommended vaccine can close doors to education, child care, and health care.¹⁰

A 2019 survey found that 51% of pediatricians indicated their offices had policies dismissing families who refuse routine childhood vaccinations.¹¹ These policies often make no distinction between families seeking minor modifications to timing and those rejecting all vaccines outright, severing crucial healthcare relationships over what could be reasonable disagreements about timing or specific interventions.

International Approaches: Different Methods, Comparable Outcomes

The assumption that American practices represent medical necessity dissolves when examining how other developed nations achieve excellent disease control with markedly different approaches.

COMPARATIVE ANALYSIS: SCHEDULE SCOPE AND TIMING

COMPREHENSIVE SCHEDULE COMPARISON					
COUNTRY	FIRST VACCINE	TOTAL BY AGE 18	EARLY EXPOSURE (0-24 MONTHS)	HEPATITIS B APPROACH	POLICY TYPE
United States	Birth (Hep B)	~73 doses, 17 diseases	~3,720-5,800 mcg aluminum	Universal birth dose	Effectively mandatory
Sweden	3 months	~36 doses, 11 diseases	~2,040-2,925 mcg aluminum	Risk groups only	Voluntary
Denmark	3 months	~33 doses, 10 diseases	~2,040-2,925 mcg aluminum	Risk groups only	Voluntary
United Kingdom	8 weeks	~57 doses, 14-15 diseases	~2,790-3,675 mcg aluminum	Universal series (no birth dose)	Voluntary (2017 added to schedule, but no tie to school attendance)

Sources: "Vaccine Schedules in all countries in the EU/EEA." *European Centre for Disease Prevention and Control Vaccine Scheduler*, accessed Jul. 9, 2025. <https://vaccine-schedule.ecdc.europa.eu/>; "Global Vaccine Schedule Comparison Chart." *Illinois Chapter, American Academy of Pediatrics*, accessed Jul. 21, 2025. <https://illinoisAAP.org/global-vaccine-schedule-comparison-chart/>; Julie Potyraj. "Measles immunization in the US." *National Foundation for Infectious Diseases*, Mar. 12, 2016. <https://www.nfid.org/measles-immunization-in-the-us/>.

American children receive nearly twice as many vaccines in their first two years compared to European nations, with an average of more than 1.5 times higher aluminum exposure during critical developmental periods.¹²

VACCINE INCLUSION PATTERNS			
VACCINE CATEGORY	ALL COUNTRIES	U.S. ONLY	VARIABLE APPROACHES
Core vaccines (DTaP, Polio, MMR, Hib, Pneumococcal)	✓ Universal	—	Consistent globally
Adult disease vaccines (Hepatitis A, Hepatitis B)	—	✓ Required	Targeted risk-based elsewhere
Individual protection (Varicella, Rotavirus, annual Influenza)	—	✓ Required	Risk groups only elsewhere

Source: "Global Vaccine Schedule Comparison Chart." *Illinois Chapter, American Academy of Pediatrics*, accessed Jul. 21, 2025. <https://illinoisAAP.org/global-vaccine-schedule-comparison-chart/>.

The pattern reveals that core vaccines are consistently used across all countries, while major differences lie in vaccines targeting adult diseases or providing primarily individual rather than community protection.

THE SUCCESS OF ALTERNATIVE APPROACHES

While no international immunization policies have had perfect results, alternative approaches have maintained good disease control through voluntary programs with high compliance rates and often have achieved rates of herd immunity superior to that of the United States.¹³ There are multiple international examples of successful control of childhood illnesses despite using more deliberate vaccination strategies, demonstrating that early, front-loaded vaccine administration is not the only method to prevent diseases.

Perhaps most tellingly, the United States underperforms compared to many peer nations in vaccination rates for the most critical vaccines despite—or perhaps

because of—its more rigid and coercive approach. While Sweden achieves 97-98% measles vaccination through voluntary programs, emphasizing education over mandates, and Japan reaches 95-98% through flexible approaches, the United States manages only 90-92% despite effectively mandatory requirements.¹⁴ While Sweden is a smaller, more homogenous country than the United States, and may have a higher baseline level of trust in public health institutions than the United States, it is not alone in achieving consistently higher rates of measles vaccination. Swedish policy includes a delayed initiation of the measles vaccine series (18 months vs 12 months), flexible vaccine options, and transparent communication. Their success indicates that strategies that emphasize respect and some degree of autonomy can yield improved confidence and compliance.

This paradox suggests that less coercive, more flexible approaches may achieve better compliance with the most critical vaccines. Context is essential in public health policy. The lesson from these international comparisons is not that all global practices should be rejected or accepted in their entirety, but successes in other countries may provide examples of alternative approaches as U.S. officials look to develop solutions to current challenges in American policy.

CHILDHOOD IMMUNITY:

A BIOLOGICAL AND DEVELOPMENTAL PERSPECTIVE

The success of these international alternatives becomes more comprehensible when we examine the biological foundations that should inform vaccination policy. Understanding how a child's immune system develops provides crucial context for vaccination policies, revealing dramatic changes in immune function that directly affect both vulnerability to disease and response to vaccines.

Immunological Maturation and Vaccine Timing

A newborn enters the world with temporary protection borrowed from its mother through maternal antibodies passed via the placenta and breast milk.¹⁵ However, this protection is both incomplete and temporary, gradually diminishing during the first months of life while the infant's own immune system functions at limited capacity.¹⁶

The infant's blood-brain barrier—the protective membrane separating circulating blood from brain tissue—is present and functional at birth, though some components continue to mature during early development.¹⁷ While the basic barrier is present and working, the transport systems that handle nutrient and drug transportation are still developing, which affects how vaccine components are processed and cleared throughout the first year of life when most vaccines are administered.

Research consistently demonstrates that the same vaccines create better antibody responses, stronger memory cells, and longer-lasting protection when

administered to older children instead of infants.¹⁸ During adolescence, the immune system develops memory capabilities equivalent to adults, leading to enduring protection rather than short-term responses.¹⁹

Consider the measles component of the MMR vaccine: Protective immunity reaches 85-95% when administered at 12 months, but provides higher protection rates at 15 months.²⁰ This difference produces measurably better protection, yet our current schedule and messaging strongly emphasize the earlier time point, despite this well-documented limitation.

Sex Differences in Vaccine Response

Throughout most of medical history, vaccine research has treated male and female bodies as equivalent in their immunization responses, despite mounting scientific evidence that biological sex affects immune responses differently.²¹

Immune system responses show among the greatest differences between males and females in human biological processes.²² Females develop stronger antibody responses to vaccines but also experience more adverse effects than males.²³ The X chromosome carries many immune regulation genes, and through X-inactivation, females may express higher levels of immune-related genes starting at birth.²⁴

The significance becomes apparent in risk-benefit assessments. Multiple international studies show that adolescent males develop myocarditis at rates ranging from approximately 1 in 2,800 to 1 in 12,400 following their second mRNA COVID-19 vaccine dose—a risk that exceeds their risk of severe COVID-19 disease in this age group.²⁵ This risk differential led multiple countries, including Nordic nations, to modify vaccination protocols for young males, demonstrating how sex-specific considerations can inform more precise vaccination approaches.²⁶

Epidemiological Timing: The Gap Between the Needle and the Need

There are instances when our current schedule fails to align the timing of vaccination with periods of actual risk. Simply put, this is another example of the gap between the needle and the need. While there are vaccines that are generally well-timed, others are administered decades before the diseases they target pose

meaningful threats—a pattern that often seems to stem from administrative convenience rather than epidemiological necessity.

This temporal disconnect creates several problems: Immunity from vaccines administered in early childhood may substantially wane by the time actual disease

VACCINATION TIMING VS. DISEASE RISK			
VACCINE	CDC TIMING	ACTUAL RISK PERIOD	TEMPORAL MISMATCH
HPV	11-12 years	Sexual debut (adolescence/early adulthood)	5-10 years
Hepatitis B	Birth, 1-2 months	Primarily adult disease (20s-30s)	20+ years
Hepatitis A	12-23 months	Severe disease limited to mid-50s and comorbid hepatitis C	50+ years

Sources: Health Care Providers. "Timing and Spacing of Immunobiologics." *U.S. Centers for Disease Control and Prevention*, Jul. 24, 2024. <https://www.cdc.gov/vaccines/hcp/imz-best-practices/timing-spacing-immunobiologics.html>; Noele P Nelson, Phillipa J Easterbrook, Brian J McMahon. "Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease." *Clin Liver Dis.*, Nov. 1, 2017, Vol. 20(4):607-628. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5582972/>; Health Care Providers. "Hepatitis A Vaccine Administration." *U.S. Centers for Disease Control and Prevention*, Jan. 31, 2025. <https://www.cdc.gov/hepatitis-a/hcp/vaccine-administration/index.html>.

risk materializes; the concentrated immunological challenge during periods of rapid development raises questions about impacts that have not been thoroughly investigated; and parents, sensing the disconnect between immediate need and present intervention, often question vaccines administered years before their perceived necessity.²⁷

Environmental Context and the Sanitation-Vaccination Synergy

The biological realities of immune development gain additional context when viewed alongside the historical relationship between environmental improvements and disease patterns. The dramatic reduction in infectious disease

mortality throughout the 20th century resulted from the intersection of multiple interventions, including both improved sanitation and vaccination.²⁸

Different diseases responded differently to sanitation improvements: Diseases spread through the fecal-oral route responded immediately to clean water and improved waste management; respiratory diseases declined with reduced household crowding.²⁹ Some highly contagious diseases, such as measles, continued to infect nearly all children despite improved living conditions, due to their extraordinary transmissibility.³⁰ Others, such as polio, highlighted the tradeoffs of sanitation—these improvements led to a shift from ubiquitous early childhood infection, which led to mild disease, to a later onset of infection that too often was catastrophic.³¹

Vaccines provided an elegant solution to the sanitation paradox—they resolved the apparent conflict between environmental improvement and disease prevention by generating immunity without infection. This synergy between sanitation and vaccination represents one of the most effective combinations in public health history.³²

This historical context reinforces the importance of distinguishing between different types of vaccines based on their relationship to environmental factors. Vaccines for highly transmissible diseases, such as measles, remain critical regardless of sanitation improvements, while vaccines for diseases primarily controlled through environmental measures may warrant different policy approaches.

HERD IMMUNITY:

ESSENTIAL, BUT NOT

APPLICABLE FOR ALL VACCINES

The biological realities of immune development and the historical success of alternative international approaches raise fundamental questions about how we classify and prioritize different vaccines. To develop more nuanced policies, we must first understand the concept that has become central to vaccination discourse, yet is frequently misapplied across the current schedule.

Herd immunity is the indirect protection that occurs when a sufficient percentage of a population is immune to an infection. It is most relevant for diseases that spread easily through casual contact, such as the inhalation of respiratory droplets.³³ Put simply, when herd immunity thresholds are met there is a break in transmission.

There are two elements to herd immunity. One is the percentage of people who are vaccinated, and this varies by disease—for measles it's 95%, for mumps it's 75-85%—but the effectiveness of the vaccine also factors in.³⁴ Recent outbreaks of measles and mumps highlight how each factor is essential. Both these diseases are vaccinated against as part of a combination vaccine, and as such, both have the same vaccination rates, just under 93%. We see outbreaks with measles because the percentage of people vaccinated is just below that needed to cause a break in transmission. Mumps outbreaks demonstrate that the percentage of the population that is vaccinated is important, it is not sufficient to create herd immunity. We see mumps outbreaks not because of sub-threshold vaccination rates, but because the vaccine is simply less effective. There are outbreaks of each disease, but the underlying reasons differ. Without both high rates of vaccination and highly effective vaccines, herd immunity is not possible.

The Misapplication of Herd Immunity Arguments

Herd immunity has become a powerful concept in vaccine discourse and is often invoked to justify every addition to the childhood schedule, regardless of a vaccine's actual contribution to community protection. Unfortunately, this vital public health concept has been stretched beyond recognition. It is applied indiscriminately to vaccines that offer little or no community protection.

The arithmetic of our current vaccine schedule reveals a fundamental oversight: Of the 17 vaccines now recommended for American children, only six contribute meaningfully to genuine herd immunity.³⁵

When parents discover that a vaccine promoted for “community benefit” offers minimal protection to others, the revelation casts doubt on other claims, including those with a solid scientific foundation. Trust, once fractured by such discoveries, is difficult to restore.

As vaccines have been added that provide individual rather than community protection, the CDC definition of vaccination has evolved: from disease prevention, to immunity, to stimulating immune response. Why do those changing words matter so much? Because they miss what makes vaccines unique. Other interventions, such as sanitation, can and have decreased the rates of infection, but only vaccines have given us breaks in transmission and disease eradication.³⁶ In shifting our focus, we lose our North Star.

A Three-Tiered Classification Framework for Vaccines

Current vaccination policy treats all childhood vaccines as equivalent community protection measures, despite substantial differences in their mechanisms and public health functions. Evidence supports a more precise three-tiered framework based on actual disease and vaccine characteristics, rather than administrative convenience.

CATEGORY 1

VACCINES CREATING TRUE HERD IMMUNITY

Six vaccines in the current pediatric schedule create genuine herd immunity that requires population-level participation: measles, mumps, rubella, varicella, diphtheria, and pertussis. These vaccines prevent both disease and transmission through casual contact, creating mathematical threshold effects that protect unvaccinated community members as well as the people who have received the vaccines.³⁷

Measles exemplifies this category. Population-level transmission breaks have a 95% threshold, and when this is reached, the vaccine protects infants too young for vaccination and immunocompromised individuals who cannot develop adequate immune responses.³⁸ The community benefit transforms individual medical decisions into matters of collective consequence and moral obligation, providing the strongest ethical foundation for vaccination requirements.³⁹

CATEGORY 2

COMMUNITY TRANSMISSION REDUCTION WITH INDIVIDUAL BENEFIT

Three vaccines provide substantial individual protection while also reducing community transmission through decreased bacterial carriage: pneumococcal (PCV13), meningococcal vaccines, and *Haemophilus influenzae* type b (Hib).⁴⁰ These function differently from true herd immunity vaccines. They decrease carriage of the culprit bacteria, and so infants are less likely to spread infection, a benefit especially pronounced in older members of the population. They lack specific population thresholds but provide genuine community benefits through reduced pathogen circulation.

CATEGORY 3

INDIVIDUAL PROTECTION WITHOUT DECREASES IN COMMUNITY TRANSMISSION

All remaining vaccines on the current schedule primarily protect individuals through various mechanisms, without meaningful decreases in community transmission. This is not to suggest there are no other potential community benefits, but from a medical standpoint, the benefits are primarily individual. Several distinct patterns emerge.

Environmental exposure without transmission: Tetanus results from soil bacteria exposure rather than person-to-person spread.⁴¹

Respiratory diseases with failed community protection: Influenza and COVID-19 are casually communicable respiratory diseases, but their vaccines provide individual benefit without demonstrable community-level protection or transmission reduction.⁴²

Behavioral transmission patterns: Hepatitis B and HPV are transmitted through specific behaviors (IV drug use and sexual contact, both being routes for hepatitis B and the latter for HPV) rather than casual contact. Hepatitis B vaccination provides individual protection, including prevention of vertical transmission by vaccinating mothers and infants, but other, theoretical community benefits have not materialized.⁴³ HPV vaccination provides individual protection against HPV-related cancers in both males and females, but the theory that vaccinating boys would reduce transmission to girls beyond the protection girls receive from their own vaccination has not been demonstrated in a consistent way in the medical literature.⁴⁴

Fecal-oral transmission without decreases in community transmission: Three vaccines provide individual protection for diseases spread by the fecal-oral route, but do not create a meaningful decrease in community transmission:

- The rotavirus vaccine prevents severe disease and hospitalization but has not consistently been shown to decrease fecal shedding, and decreases in morbidity and mortality have tracked with the absolute number of vaccinations rather than showing the multiplier effect that would be expected from a reduction in community transmission.⁴⁵
- The hepatitis A vaccine successfully eliminated (the always mild) disease in children but failed to provide the intended community protection for vulnerable adult populations that was the basis for it being added to the pediatric schedule.⁴⁶
- The inactivated polio vaccine (IPV) provides individual protection by decreasing the likelihood of developing paralytic polio, but does not prevent infection or reduce community transmission.⁴⁷

VACCINE CLASSIFICATION BY PUBLIC HEALTH FUNCTION

CATEGORY	FUNCTION	VACCINES
CATEGORY 1: True Herd Immunity	Create mathematical thresholds for community protection through interrupted transmission	Measles, Mumps, Rubella, Varicella, Diphtheria, Pertussis
CATEGORY 2: Community Transmission Reduction	Reduce bacterial carriage and community circulation; individual plus community benefit	Pneumococcal (PCV13), Meningococcal, Haemophilus influenzae type b (Hib)
CATEGORY 3: Individual Protection Only	Protect individuals without meaningful community transmission reduction	Tetanus, Influenza, COVID-19, Hepatitis B, HPV, Rotavirus, Hepatitis A, Polio (IPV)

CASE STUDY:

The Evolution of Polio Vaccination Strategy

The transition from oral polio vaccine (OPV) to inactivated polio vaccine (IPV) provides the clearest illustration of how different vaccine formulations serve different public health functions, perfectly demonstrating the three-tier framework in action.

OPV functioned as a Category 1 vaccine: The OPV created genuine herd immunity through community transmission of the live vaccine virus. In countries such as the United States, which had high levels of sanitation, herd immunity thresholds and breaks in transmission occurred when 80-85% of the population was vaccinated.⁴⁸ Live vaccine doses were swallowed by the recipient, went on to multiply in the gut, and then were shed in feces. This also provided opportunities for “secondary vaccination” of unvaccinated contacts, and depended on a lack of individual cleanliness. When a vaccinated individual used the bathroom and didn’t wash up afterwards, the simple act of shaking hands led to that person passing on polio-laden fecal particles to the next person he encountered. When that person touched his hands to his mouth, he, in turn, would ingest a tiny, micro-dose of polio vaccine. In areas of the world with low sanitation, this secondary vaccination mechanism allowed for transmission breaks at even lower overall vaccination rates, requiring only around 50% of the population to be vaccinated to achieve herd immunity.

IPV functions as a Category 3 vaccine in children: While, in theory, IPV can support community protection in people who previously have received the OPV, the OPV hasn't been given in the United States in 25 years. For children who have not received the OPV—ALL children and adolescents in the United States—it does not prevent intestinal infection or viral shedding.⁴⁹ Children who get the IPV are protected against developing paralytic disease, but IPV does not meaningfully cut the risk of acquiring or spreading infection. No matter how many people are vaccinated, breaks in transmission are not observed. Think of it like a seatbelt—it protects the person wearing it from serious harm, but doesn't make other drivers any safer.

While OPV had been successful in eradicating polio, the fact that it was a live virus meant there was a very small (1 in 2.4 million) but real risk that unvaccinated people in the population could contract polio through contact with a person who had received the vaccine.⁵⁰ This led to a shift from the OPV to IPV, with the last OPV given in the United States in 2000.

This distinction carries profound implications for policy justification and public communication. Arguments for mandating OPV based on community protection were scientifically sound. There were herd immunity thresholds, and vaccinating a predefined percentage of the population could and did lead to breaks in transmission. Individual vaccination decisions genuinely affected community welfare. If too many people declined vaccination, then outbreaks could occur. Arguments for mandating IPV using identical community protection rationales are scientifically unsound and inappropriately suggest that parents who do not get their children vaccinated with the IPV endanger other children.

Decisions related to whether or not to consider requiring IPV come down to this: When do parents lose their rights to make medical decisions for their children? An individual child who is not vaccinated against IPV does not place other children at risk. The consequence for a parent who does not buckle up his child is a fine, not the loss of access to public education. Precision in messaging is necessary for both scientific integrity and public trust, and any consequences should be proportionate.

This three-tiered framework provides the foundation for understanding how legal precedents, economic forces, and historical developments have shaped current vaccination policy in ways that often extend beyond the original epidemiological justifications for vaccine requirements.

HISTORICAL LEGAL CONTEXT:

JACOBSON AND THE EVOLUTION OF VACCINE AUTHORITY

The three-tier classification framework reveals fundamental distinctions between vaccines that require different policy approaches and ethical justifications. To understand how current mandates extend far beyond their original constitutional foundations, we must examine the legal precedents that established vaccine authority and the economic forces that have driven policy expansion.

The Constitutional Foundation: *Jacobson v. Massachusetts* (1905)

When examining the current landscape of vaccine mandates, it is instructive to return to the foundational legal case that established the constitutional basis for public health interventions. Compulsory smallpox vaccination had been implemented for several decades in cities across the United States in the 1800s, and public opposition to those mandates had been present for nearly as long. In *Jacobson v. Massachusetts* (1905), the Supreme Court upheld the authority of states to enforce compulsory vaccination laws, balancing individual liberty against public necessity during a smallpox outbreak.⁵¹

This landmark case established important principles that have guided public health law for over a century, but the context of the decision is crucial to understanding its

appropriate applications and limitations.⁵² The Court was addressing smallpox—a highly contagious disease that spread through casual contact, had a mortality rate of approximately 30% in unvaccinated populations, posed an immediate threat to the entire community, and was countered by an intervention that primarily benefited the community, not just individuals.⁵³ Notably, the mandate—which only applied to adults and which had a fine as the penalty for noncompliance—was implemented during an active smallpox outbreak as an emergency measure.⁵⁴

While the term “herd immunity” would not enter common usage for decades, the Court was fundamentally grappling with what we now recognize as a classic Category 1 herd immunity scenario.⁵⁵ The community understanding, which proved scientifically correct, was that smallpox was so contagious and spread so easily through casual contact that without universal vaccination, effective protection was impossible—including protection for those who, for medical reasons, could not be vaccinated themselves.⁵⁶

The Court heard Jacobson’s testimony that part of his refusal was based on having seen the “great and extreme” suffering his son had experienced after being vaccinated, but had rejected this concern, comparing vaccination to the military draft: a situation where we knowingly send individuals into harm’s way for the collective good, acknowledging that some will be injured or killed in the process. This framing recognized that vaccines carry risks; some individuals will be harmed or even might die, and such risk is justified only by an overriding public health necessity that requires population-level participation to achieve community protection.

Justice Harlan, writing for the majority, specifically noted that the power to mandate medical interventions was not unlimited, stating that public health powers must not be used in an “arbitrary, unreasonable manner” or go “far beyond what was reasonably required for the safety of the public.”⁵⁷

The Expansion Beyond *Jacobson*’s Constitutional Framework

The *Jacobson* precedent was quickly expanded beyond its emergency origins. In *Zucht v. King* (1922), the Supreme Court extended vaccination authority to children through school entry requirements even without active outbreaks.⁵⁸ What had been emergency powers with a potential financial impact on adults during a smallpox epidemic became routine educational requirements—a transformation

from crisis response to administrative convenience that fundamentally altered the constitutional balance between individual liberty and state authority.

Today, vaccine mandates have expanded far beyond this original scope to include vaccines for diseases that differ significantly from smallpox in their transmission characteristics, severity, population impact, and risk distribution.⁵⁹ Smallpox represented a classic example of a disease that was casually communicable. It spread easily through routine or incidental interactions between individuals, and did not require prolonged or intimate contact. By contrast, many diseases on the current schedule are not casually communicable, have much lower mortality rates, pose limited or no threat of community outbreaks, and present minimal risk to children.

The legal framework established in *Jacobson* was designed for Category 1 vaccines—those that create genuine herd immunity and require population-level participation for community protection. The application of this framework to Category 2 and Category 3 vaccines represents a fundamental expansion beyond the original constitutional justification—though it may be supportable on different grounds, such as preventing severe individual harm.

The Institutional Enforcement Architecture

While, officially, the pediatric vaccine schedule consists of recommendations, a variety of enforcement mechanisms effectively make them mandates. The ability to attend school, participate in sports, or even be seen by a pediatrician is often limited if there are any deviations from the schedule, even if proposed changes would have no impact on other children.

Consider a mother whose family history of autoimmune disease prompts her to request a slightly modified vaccine schedule for her infant. Her reasonable caution—one that would be respected in nearly any other medical context—could result in her family's dismissal from their pediatric practice.

The school and daycare gateway represents perhaps the most powerful mandate enforcement mechanism. While religious and philosophical exemptions technically exist in some states, obtaining them has become increasingly difficult.⁶⁰ Parents seeking these exemptions face bureaucratic obstacles, required “education” sessions designed to change their minds, and sometimes outright hostility.

Even insurance companies and healthcare systems have joined this enforcement structure. Physicians face financial penalties when their patient populations fall below

vaccination targets.⁶¹ Electronic health records prominently flag “non-compliant” patients, creating pressure on providers to coerce rather than discuss. The language itself reveals the underlying assumption: Not following every recommendation constitutes “non-compliance,” a term borrowed from addiction medicine that implies irrationality and defiance rather than informed, let alone shared, decision-making.

The Economics of Vaccine Development and Policy

Understanding the economic forces shaping modern vaccination policy is essential for evaluating the gap between official justifications and the institutional incentives that drive policy decisions. These forces operate largely outside public view, yet profoundly influence which vaccines are developed, how they are priced, and whether they become mandatory.

Vaccine development requires investments of \$500 million to more than \$1 billion across 10-15 years, as well as a willingness to assume the risks of potential failure related to the epidemiology of the disease in question.⁶² Disease epidemiology and market share often dovetail; if a disease applies to a limited population, a vaccine is less likely to be developed than if universal vaccination is deemed necessary.

A vaccine that is included in the childhood schedule essentially receives a captive market of approximately 3.6 million births annually in the United States, with demand guaranteed by legal requirements rather than consumer choice.⁶³ When a vaccine achieves inclusion in the schedule, it creates significant financial benefits for manufacturers through guaranteed markets and complete protection from liability—a unique situation unlike any other medical innovation.⁶⁴

The Shift from Mortality to Economics

Traditional vaccine advocacy focuses on preventing death and severe illness, but modern vaccine schedules increasingly include interventions whose economic benefits equal or exceed their morbidity and mortality benefits. This shift is especially notable in developed nations with advanced healthcare systems (and correspondingly high levels of sanitation), where diseases that remain common

causes of childhood deaths in impoverished nations primarily cause healthcare utilization and economic disruption in wealthy countries.

Consider rotavirus vaccination in the United States. Before vaccination, the disease caused relatively few deaths—approximately 20-60 annually—thanks to widespread access to hospital care and IV rehydration.⁶⁵ However, it imposed enormous costs: 70,000 hospitalizations, 200,000 emergency room visits, 400,000 outpatient visits, and \$1 billion in annual healthcare costs and lost productivity.⁶⁶ Vaccination did lead to elimination of these small numbers of deaths—certainly a good thing—but the primary benefit in the United States has been economic, with decreases in acute care utilization for hydration and supportive care driving this savings.

This pattern reveals how vaccine value assessment has fundamentally shifted in wealthy countries. Many vaccines now offer economic rather than epidemiological advantages, transforming the risk-benefit calculation in ways that public messaging rarely acknowledges.⁶⁷

CASE STUDY:

Hepatitis B Vaccination—Economics Over Epidemiology

The hepatitis B vaccination program illustrates how economic incentives can drive universal approaches even when targeted interventions would achieve equivalent protection. When hepatitis B vaccination was added to the U.S. childhood schedule in 1991, policymakers faced a disease with very specific transmission characteristics and risk populations.⁶⁸

In the United States, hepatitis B transmission occurs through three routes: injection drug use (by far the most common route, and almost exclusively in adult men), sexual contact (a much smaller risk group, comprised mostly of men-who-have-sex-with-men and have multiple partners), and extremely rarely, vertical transmission from infected mothers to their infants during birth.⁶⁹ The at-risk population for vertical transmission in the United States always has been and remains tiny but identifiable—it includes women with chronic hepatitis B infection who were immigrants from countries where the disease was endemic (they did not contract the disease in the U.S.), and to a much lesser extent it also included women who had become infected

by male partners who were intravenous drug users (IVDU)—representing about 1% of the approximately 3.6 million births occurring annually.⁷⁰

THREE JUSTIFICATIONS WITH DIFFERENT OUTCOMES:

Preventing Vertical Transmission: The most solid justification for hepatitis B vaccination—and the justification for the universal birth dose—was preventing mother-to-child transmission in this small high-risk population.⁷¹ Most people in this group were poor, linguistic barriers were often an issue, and prenatal care was limited. However, rather than addressing barriers to healthcare access through improved screening systems and targeted interventions for women at high risk, universal vaccination was chosen. This was a matter of administrative convenience. It was easier and cheaper to provide vaccines than outreach structures, and by vaccinating all babies, public health authorities also hoped to avoid the stigma that a targeted campaign might confer. This meant that millions of babies born to mothers who were known to be negative for hepatitis B (universal screening started in 1988), babies who had ZERO risk of infection, were vaccinated in the name of convenience and equity.

Preventing Horizontal Transmission: Public health messaging included prevention of horizontal transmission—infection through casual contact with infected family members.⁷² This justification—which was the basis for later vaccinations given to infants—drew on patterns observed in endemic countries but was never a meaningful route of infection in the United States. Horizontal transmission depends on both high viral loads and poor sanitation.⁷³ Without both factors, it simply doesn't happen, and this is why it never was an issue in the U.S., even among immigrant populations.

Eradicating the U.S. Viral Reservoir: The most ambitious justification for embarking on universal vaccination was eradicating hepatitis B from the U.S. viral reservoir entirely. Since most American hepatitis B infections occur among IVDUs in their twenties, vaccinating infants would theoretically provide protection when these individuals reached the age of highest risk.⁷⁴ When the vaccine was added to the schedule in 1991, the evidence at that time suggested the birth and infant doses would provide lifelong immunity.⁷⁵ Evidence that this assumption was incorrect was available within a decade. By the mid-2000s, there was published literature that demonstrated that antibodies waned significantly over time.⁷⁶ A 2022 study confirmed that nearly three-quarters of people had lost protective

antibodies by age 16-20, the age at which the risk of initiating IVDU jumps. The definitive evidence of this policy failure is that 35 years after the vaccination campaign began, hepatitis B infections continue among injection drug users at rates suggesting there has never been any meaningful protection of this group from infant vaccination.

Hepatitis B vaccination had three pillars of support, one which has been proven correct, vaccinating high-risk mothers to prevent vertical transmission works; one which never had a legitimate scientific basis, horizontal transmission was never a risk in the U.S.; and a third, vaccinating babies in order to prevent the risk to adult IVDU, but which we now know, and have known for nearly 20 years, was an incorrect hypothesis.

Setting aside the ethical issues in using infants as instruments of social policy to address a disease acquired by adult behaviors, what is the justification for continued universal vaccination at birth and in infancy? Market forces offer one potential explanation. The current system represents an annual market of more than \$500 million in vaccine acquisition alone.⁷⁷ A targeted campaign for the one pillar that does have medical and ethical justification—addressing vertical transmission risks among immigrants from endemic countries—would drop that by at least 10-fold, to around \$50 million per year.⁷⁸

The hepatitis B program illustrates how economic considerations can perpetuate policies even after their scientific justifications fail. The current universal approach creates a robust market: Approximately 3.6 million births annually receive the birth dose, plus subsequent doses. A targeted approach focusing on actual risk populations would dramatically reduce market size while achieving equivalent protection for the populations at risk.

It is worth considering the counterargument. What's the harm in vaccinating all newborns "just in case?" Hepatitis B is a disease that has no cure, and infection at birth can lead to serious chronic illness. One of the justifications for universal vaccination has been the possibility that a mother could test negative and still transmit the virus to her child. However, a review of the medical literature failed to identify any case reports or other publications of this occurring in the United States. Even a vaccine deemed generally safe can cause severe harm, and administering it to millions of infants each year, infants who have no risk of disease, cannot be justified solely on theoretical grounds.

Real-world harms, though rare, have been reported. From 2005 to 2015, 20,231 adverse events following hepatitis B vaccination (most vaccinations are in children, and half the adverse events that have been reported are in children younger than two years of age) were reported to the Vaccine Adverse Event Reporting System (VAERS).⁷⁹ As of June 2025, at least 780 injury claims and 63 death claims had been filed with the Vaccine Injury Compensation Program (VICP) related to hepatitis B vaccination, and 318 of those claims were compensated.⁸⁰

The problem of hepatitis B in American infants is a problem of access for underserved populations: immigrants from countries where hepatitis B is endemic, or women whose partners are injection drug users. The universal strategy, while well-intended, institutionalizes neglect. In 2023, 2.3% of U.S. mothers received no prenatal care.⁸¹ Vaccinating all newborns does not solve the problem; it diverts resources from creating the infrastructure necessary to reach vulnerable families. Social, linguistic, economic, and cultural outreach would not only better address hepatitis B risk but also create enduring pathways for maternal health, early childhood services, and future public health initiatives far beyond hepatitis B itself.

THE PERFECT STORM OF THE 1980S:

A DECADE THAT SHAPED MODERN VACCINE POLICY

The legal precedents and economic incentives described above created the framework within which vaccination policy could expand, but they do not fully explain how American policy evolved from seven targeted vaccines to today's comprehensive schedule. To understand this transformation, we must examine the convergence of forces in the 1980s that made universal approaches seem not just preferable, but practically inevitable.

This decade witnessed a perfect storm of healthcare system changes, technological constraints, and public health challenges that collectively favored broad, standardized interventions over targeted, individualized approaches. The transformation did not occur through conscious design but through the interaction of multiple pressures that pushed the system toward maximum inclusion rather than selective targeting.

Healthcare Fragmentation and the Challenge of Targeted Interventions

The 1980s healthcare landscape created what might be termed the “unreachable population problem”—a situation where the groups at highest risk for many diseases existed almost entirely outside formal healthcare systems.⁸² This

fragmentation created profound challenges for traditional targeted public health approaches and made universal strategies appear more reliable and equitable.⁸³

Hepatitis B was added to the pediatric schedule in 1991, but children were never the primary driver of this decision.⁸⁴ Vertical transmission to newborns was rare outside of a specific immigrant population, and horizontal transmission to infants and toddlers was essentially nonexistent.⁸⁵ The populations at true risk for hepatitis B— injection drug users, men having sex with men, people experiencing homelessness—had complex relationships with formal healthcare systems.⁸⁶

Traditional targeted approaches had failed to reach these populations across multiple disease areas due to structural barriers: economic constraints, transportation difficulties, irregular schedules, mistrust of institutions, immigration status concerns, and stigma associated with risk factors.

Simultaneously, the rise of managed care fundamentally altered medical decision-making patterns.⁸⁷ What had been intimate relationships between individual physicians and their patients became standardized, system-level processes optimized for population metrics rather than individual needs. Quality metrics emerged that rewarded high rates of intervention delivery without distinguishing between vaccines preventing imminent childhood death and those offering more attenuated benefits.⁸⁸

Technological Constraints and the AIDS Crisis Influence

The technological limitations of the 1980s reinforced these trends toward universal interventions. Electronic health records barely existed.⁸⁹ Laboratory results took days, not hours. Identifying high-risk populations required manual processes that were both labor-intensive and error-prone.⁹⁰ In this technological environment, universal approaches represented a feasible strategy for ensuring population coverage.

Perhaps most significantly, an entire generation of public health professionals was shaped by the HIV epidemic.⁹¹ Having witnessed AIDS devastate precisely the populations that traditional health care consistently failed to reach, physicians who led public health systems carried profound skepticism about targeted approaches into subsequent policy decisions.⁹² The HIV experience led these officials to a

stance that infectious diseases don't respect social boundaries and that failure to protect marginalized populations ultimately threatens everyone. The reality that risks were different across populations was ignored. Taking the position that everyone was at equal risk was considered essential to avoiding the stigma that targeted approaches might lead to. It was easier and cheaper to take a blanket approach.

This lesson, while potentially valid in the context of sexually transmitted infections, became generalized to other disease categories where the same transmission dynamics didn't necessarily apply. Universal strategies appeared more equitable and reliable than risk-based interventions that were seen as having reinforced existing health disparities in the past.⁹³ But if vaccines were going to be used more broadly as a mechanism of addressing societal concerns, there would need to be structures in place to address the attendant financial and malpractice risks. Congress took note, and by the mid-1980s, a solution was instituted—the National Childhood Vaccine Injury Act.

The 1986 Watershed: The National Childhood Vaccine Injury Act

The passage of the National Childhood Vaccine Injury Act of 1986 represents the single most consequential policy change in modern vaccination history.⁹⁴ While ostensibly designed to address a vaccine supply crisis, the Act fundamentally altered the economic and legal landscape surrounding childhood vaccination.

THE CRISIS THAT PROMPTED CHANGE

By the early 1980s, vaccine manufacturers faced an existential threat. The number of liability suits against vaccine makers rose dramatically, from nine cases between 1978 and 1981 to more than 200 suits per year by the mid-1980s.⁹⁵ Large jury awards and mounting legal costs created an environment where manufacturers found vaccine production financially unsustainable.⁹⁶ Insurance costs escalated dramatically, and manufacturers had increasing difficulty obtaining liability coverage at any price.

By 1985, vaccine manufacturers had difficulty obtaining liability insurance, and only one company was still manufacturing the pertussis vaccine in the United States.

The prospect of vaccine shortages presented policymakers with an unacceptable scenario where diseases that had been controlled for decades could return.⁹⁷

THE LEGISLATIVE SOLUTION AND ITS CONSEQUENCES

The 1986 Act created an elegant solution to the liability crisis while establishing mechanisms that would profoundly influence future policy development. The legislation established the Vaccine Injury Compensation Program (VICP), a no-fault system designed to provide compensation to those injured by vaccines without requiring families to prove manufacturer negligence.⁹⁸

In exchange for this compensation system, manufacturers received protection from most lawsuits.⁹⁹ The legislation succeeded in its primary goal of ensuring vaccine supply. Companies returned to vaccine manufacturing, shortages were averted, and the public health infrastructure remained intact. However, the Act had consequences that would reshape the entire landscape of childhood vaccination policy.

THE TRANSFORMATION OF RISK CALCULATIONS

The 1986 Act fundamentally altered the risk-benefit calculations that had previously constrained vaccine development and policy expansion. Before the legislation, adding a new vaccine to the recommended schedule carried enormous financial risk for manufacturers. The Act changed this calculation entirely. When the risk of catastrophic liability was removed, the economic incentives naturally shifted toward expansion rather than restraint. It also supported a shift in philosophy: Vaccination no longer had to be limited to those that were essential to address population-level, casually communicable diseases that addressed childhood illness.

THE UNPRECEDENTED EXPANSION

The temporal association between this liability protection and the expansion of the childhood vaccine schedule was undeniable. American children in the mid-1980s typically received vaccines against seven diseases by age 18: diphtheria, tetanus, pertussis, polio, measles, mumps, and rubella.¹⁰⁰ These vaccines mostly targeted diseases that spread through casual contact and posed immediate threats to child health or community welfare—primarily Category 1 vaccines in our classification framework.

The expansion began almost immediately after the Act's passage: Hib vaccine in 1989, hepatitis B for all infants in 1991, varicella in 1996, pneumococcal disease in 2001, influenza for all children in 2002, rotavirus and hepatitis A in 2006, and HPV and meningococcal disease in 2010.

Between 1989 and 2010, ten additional vaccines entered the routine childhood schedule, representing a 143% increase from the original seven. Notably, many of these additions were Category 2 and Category 3 vaccines that provide individual protection or limited community benefit, rather than the Category 1 vaccines that had historically justified universal approaches.

The Rise of Combination Vaccines and Reduced Choice

As the schedule expanded, practical challenges emerged around vaccine administration. The solution came through combination vaccines that packaged multiple antigens into single injections.¹⁰¹ While these offered genuine advantages in terms of visit efficiency and patient comfort, they also created new problems that persist today.

When multiple vaccines are combined into single products, it becomes impossible for families to make selective decisions about individual components. A parent with concerns about one specific vaccine must accept or reject the entire combination. This loss of granular choice inadvertently contributed to the all-or-nothing nature of current vaccination decisions, driving families toward complete rejection rather than selective acceptance.

This was particularly true for the combined Measles/Mumps/Rubella (MMR) vaccine, which was first released as a combination shot in 1971. In the 1990s, concerns about the potential association between MMR vaccination and autism were raised.¹⁰² Additionally, some parents had concerns about individual components, including the rubella component, because this was a live vaccine and natural rubella infection can cause neurological complications, while others questioned the necessity of mumps vaccination, given the typically mild nature of mumps infection in children.

Without weighing in on the validity of those concerns, the combination vaccine as the default had an unfortunate consequence. Regardless of whether concerns

were driven by the combination of all three vaccines or a specific component drove individual concerns, the combined format meant that parents with reservations about any single component had to opt out of all three. This had its greatest impact on measles vaccination coverage, since measles requires the highest vaccination rates to maintain herd immunity—approximately 95%—making it most vulnerable to declines in the combined vaccine’s uptake.¹⁰³

These combinations also muddled the interpretation of complications. When a child had an adverse event after being exposed to multiple antigens, it became next to impossible to determine which was the culprit.¹⁰⁴

The Establishment of Inadequate Safety Monitoring

Recognition that removing traditional liability mechanisms required enhanced safety monitoring led to the establishment of new surveillance systems designed to detect potential problems. These systems, while well-intentioned, had limitations that persist today.

Vaccine Adverse Event Reporting (VAERS) emerged from the same legislation that created liability protections.¹⁰⁵ The system was designed as a passive surveillance mechanism, but studies suggest VAERS captures between 1-10% of adverse events, creating systematic blindness to many of the signals it was designed to detect.¹⁰⁶ Even VAERS’s celebrated successes revealed its limitations.

The first version of the rotavirus vaccine had an uncommon but severe side effect, intussusception (a twisting of the intestines that is incredibly painful and can be fatal).¹⁰⁷ VAERS reports led to the intussusception-adverse event detection, which precipitated a change to a new formulation. While a great success, this episode also highlighted a primary limitation of VAERS. It required a 1 in 10,000 adverse event rate to generate sufficient reports for signal detection.

Consider that there are around 22 million children five years of age or younger in the United States.¹⁰⁸ A vaccine-related adverse event of 1 in 20,000 would not be expected to be detected by VAERS but would be expected to occur in more than 1000 children.

The Vaccine Safety Datalink (VSD) was created to address VAERS’s limitations through active surveillance, but VSD covers only 3% of the U.S. population and

focuses primarily on predetermined outcomes.¹⁰⁹ There is a very limited list of complications that “count.” When the primary safety monitoring system captures less than 10% of events and the secondary system examines only 3% of the population for preselected problems, the surveillance infrastructure reveals itself as inadequate for comprehensive safety monitoring.

The Medicalization of Social Policy

Perhaps the most significant conceptual shift of this era was the increasing use of medical interventions to address social problems that resisted direct policy solutions. Rather than developing effective strategies for reaching high-risk adult populations or addressing social determinants that made certain groups vulnerable, policymakers increasingly turned to universal childhood vaccination as a more administratively convenient approach.

While ethically dubious, the approach had intuitive appeal: If you can’t reach the adults at risk, protect them by vaccinating the children. While, in theory, this could have worked, in practice, the attempts to use the pediatric vaccine schedule this way failed to achieve their intended results. Hepatitis A, a vaccine still in the schedule, serves as an example of this failure.

CASE STUDY:

Hepatitis A and the Failure of Medicalized Solutions

The hepatitis A vaccination program provides a clear example of how the medicalization of social policy can fail to achieve its intended objectives while creating an illusion of progress. Universal childhood vaccination began in 2006, justified not by risks to children—who typically experience mild or asymptomatic infections—but by theoretical transmission chains connecting children to vulnerable adults.¹¹⁰

What was the problem that public health officials were trying to solve? Some men in their 50s and 60s who had hepatitis C (contracted through IVDU) and were homeless had a devastating consequence if they contracted hepatitis A.¹¹¹ In this

population, hepatitis A wasn't a mild disease. It could lead to rapid, severe liver failure, a complication that resulted in thousands of hospitalizations and around 150 deaths each year.

The theory was that children—in whom hepatitis A was a common, mild disease—were a reservoir of disease in the population.¹¹² This meant that if a caregiver changed the diaper of an infected baby and didn't wash her hands well, and then went to work in a food processing plant, and then didn't wear her gloves at work, and then touched produce with her dirty hands, and then that bag of infected produce was purchased by a soup kitchen, and then an adult with hepatitis C ate that serving of contaminated spinach, that he could acquire a hepatitis A superinfection. This was the rationale for vaccinating infants. It was based on a chain of causality that frankly was inconceivable.

This theory received an unintended but definitive test through what amounted to one of the most important natural experiments in modern public health. Universal childhood vaccination successfully eliminated hepatitis A among children by 2010.¹¹³ If children had indeed served as the primary disease reservoir for adult infections, severe adult disease should have decreased accordingly.

Instead, the opposite occurred. Between 2016 and 2022, hepatitis A outbreaks primarily affecting homeless populations resulted in over 27,000 cases, 8,500 hospitalizations, and 315 deaths.¹¹⁴ Most of these deaths occurred among men with a median age of 55—precisely the population the childhood vaccination program was designed to protect.

The hepatitis A experience demonstrates how the medicalization of social policy can fail while creating an illusion of progress. After 19 years of universal vaccination (and an additional 10 years of regional vaccination preceding this broader campaign) and hundreds of millions of doses, we have successfully eliminated a disease that posed no meaningful threat to the population receiving the intervention, babies and young children. At the same time, the vulnerable population we intended to protect experienced a doubling of the rates of severe injury and death. Addressing members of traditionally underserved populations is an incredibly challenging task, but using children as unwitting proxies for failures of outreach is not compassionate; it is performative.

EVIDENCE GAPS AND MISAPPLIED STANDARDS

The institutional changes of the 1980s not only transformed vaccination policy but also created new challenges in how we evaluate evidence and communicate about vaccine safety. These challenges persist today and contribute to the growing crisis in public trust that threatens the entire vaccination enterprise.

The Mismatch: Population Evidence for Individual Benefits

The transformation of vaccination policy from targeting diseases that require universal participation to provide community protection to including vaccines that primarily benefit individuals has created a fundamental mismatch between the evidence standards we apply and the actual functions these vaccines serve. This mismatch has profound implications for both safety assessment and public communication.

When vaccines serve genuine herd immunity functions—protecting communities through interrupted transmission—population-level evidence standards make perfect sense. If a vaccine prevents community outbreaks, then population-level studies showing broad safety and effectiveness directly support the community protection goals that justify mandate policies.¹¹⁵ The ethical framework that accepts some individual risk for collective benefit aligns with statistical approaches that focus on population outcomes rather than individual variation.

However, when vaccines primarily protect individuals—as most vaccines on the current schedule do—applying the same population-level evidence standards creates both scientific and ethical problems. We use statistical approaches designed to evaluate community interventions to justify individual medical decisions, while simultaneously using community protection rhetoric to promote vaccines that provide primarily personal benefits.

Consider the logical inconsistency: Hepatitis B vaccination provides individual protection, as demonstrated by the success in decreasing vertical transmission among immigrant women who come to the U.S. already positive for the disease.¹¹⁶ But the policy of universal childhood vaccination to reduce infection in adult IDU has been a failure.¹¹⁷ Why do we rely on population-level safety data to justify mandating this individual intervention? For vaccines that function like personal protective equipment, shouldn't safety standards emphasize individual risk factors, genetic susceptibility, and personalized risk-benefit calculations rather than population averages?

This misalignment becomes particularly problematic when addressing vaccine safety concerns. Parents who observe potential adverse reactions in their children are told that population studies show “no association,” as if population-level statistical findings can definitively rule out individual susceptibility. This approach misrepresents what population studies can and cannot tell us about individual risk.

Inconsistent Standards for Evidence Quality

The selective application of evidence standards reveals institutional bias rather than scientific rigor. Current practice accepts certain types of evidence when it supports policy, while dismissing identical evidence when it questions policy—a pattern that undermines the credibility of “evidence-based” claims.

ECOLOGICAL STUDIES: ACCEPTED WHEN CONVENIENT, DISMISSED WHEN INCONVENIENT

An ecological study examining aluminum adjuvant exposure across multiple countries found statistically significant correlations with autism prevalence in a population exceeding 300 million people across eight countries. The research

identified significant associations across seven of nine autism parameters examined.¹¹⁸ The statistical power required to detect signals in a dataset of this magnitude across diverse healthcare systems is extraordinary—ecological studies rarely achieve such robust findings.

Yet the World Health Organization dismissed these findings purely because they were “ecological” studies that could not establish individual causation.¹¹⁹ Ecological studies certainly have significant limitations, but these same agencies routinely cite ecological studies when they support current policies. A Danish ecological study showing continued autism increases after thimerosal removal is frequently presented as definitive evidence against thimerosal-autism associations.¹²⁰

This selective application represents institutional bias rather than consistent methodological standards. If ecological studies lack validity for policy decisions, this limitation should apply universally, not selectively based on whether findings support or challenge current practices.

Confidence for Populations, Uncertainty for Individuals

Large-scale epidemiological studies examining vaccine safety typically report “no significant association” when confidence intervals cross 1.0, but this statistical convention obscures crucial nuances that public messaging consistently ignores. When a confidence interval spans both sides of 1.0 (the line of no effect), it means the study cannot determine whether the intervention is protective or harmful at the population level. The data are consistent with both possibilities: The true effect could lie anywhere within that range, from protective (below 1.0) to harmful (above 1.0).

Public health communications routinely transform this statistical uncertainty into definitive safety claims, suggesting that “no significant association” means “no risk” (a fundamental misrepresentation of what population-level studies can actually tell us about individual susceptibility).

The population-level lack of association has been inappropriately transformed to suggest that individual adverse reactions cannot occur. This transformation obscures a harsh reality: When medical interventions are applied to millions of

INTERPRETING STATISTICAL FINDINGS

STUDY	CONFIDENCE INTERVAL	OFFICIAL INTERPRETATION	ACTUAL MEANING
Madsen et al. (2003)	0.68–1.24	“No association found”	No statistically significant association at the population level; individual risk cannot be ruled out
Hviid et al. (2003)	0.60–1.20	“Study shows safety”	No statistically significant association at the population level; confidence interval includes increased risk
Andrews et al. (2004)	0.81–0.93	“No evidence of harm”	No statistically significant association at the population level; some analyses showed protective effects

Sources: Kreesten M Madsen, Marlene B Lauritsen, Carsten B Pedersen, et al. “Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data.” *Pediatrics*, Sept. 2003, Vol. 112(3 Pt 1): 604-6. <https://pubmed.ncbi.nlm.nih.gov/12949291/>; Anders Hviid, Michael Stellfeld, Jan Wohlfahrt, and Mads Melbye. “Association between thimerosal-containing vaccine and autism.” *JAMA*, Oct. 1, 2003, Vol. 290(13):1763-6. <https://pubmed.ncbi.nlm.nih.gov/14519711/>; Nick Andrews, Elizabeth Miller, Andrew Grant, Julia Stowe, Velda Osborne, and Brent Taylor. “Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal association.” *Pediatrics*, Sept. 2004, Vol. 114(3):584-591. <https://pubmed.ncbi.nlm.nih.gov/15342825/>.

children, even interventions that are generally safe at the population level will be associated with at least some individuals experiencing harm. Rare events become statistical certainties at scale.

The Institute of Medicine Report: Limitations Misrepresented as Certainty

In 2013, the Institute of Medicine published “The Childhood Immunization Schedule and Safety,” a comprehensive review that has been systematically misrepresented in public health communications.¹²¹ (The Institute of Medicine has since been renamed the National Academy of Medicine, but this paper refers to it by its original name, as that was the organization that conducted and published

this study.) While officials cite this report as evidence supporting current practices, the report's actual conclusions reveal profound gaps in our understanding.

The IOM committee explicitly acknowledged the limitations of its findings: "Studies designed to examine the long-term effects of the timing and number of immunizations have not been conducted." They noted that "[e]vidence is inadequate to accept or reject a causal relationship between aspects of the immunization schedule and autoimmune diseases, seizures, and neurodevelopmental disorders other than autism." Most remarkably, they found that "[n]o studies have compared the differences in health outcomes between entirely unimmunized populations of children and fully immunized children."

This represents a remarkable admission: The comprehensive schedule that defines pediatric health care has never been studied in its entirety compared to alternative approaches. Despite these explicit acknowledgments of evidence gaps, public health officials immediately characterized the IOM report as validation of current practices.

Critical Evidence Gaps in an Expanded Schedule

The expansion of the childhood vaccination schedule from seven vaccines in the 1980s to 17+ vaccines today occurred without a systematic study of several critical areas:

Cumulative Effects of the Complete Schedule: No comprehensive studies examine the safety of the complete vaccination schedule as currently implemented. We know how individual vaccines perform in isolation, but we lack systematic data on how multiple vaccines interact when administered simultaneously or in close sequence.

Timing Optimization Studies: Limited research compares the current compressed schedule to more spaced approaches that might align better with immune system development. The front-loading of vaccines in early childhood reflects administrative convenience rather than immunological optimization.

Individual Risk Factors: For vaccines that provide individual protection only, research should emphasize individual susceptibility factors, genetic variations, and personalized risk-benefit calculations. Instead, we apply population-level safety data uniformly, ignoring the very individual variations that would be central to any other personal medical decision.

Aluminum Exposure: Vaccines are the Primary Driver

The expansion of the vaccination schedule has fundamentally altered patterns of aluminum exposure during early development, yet this change has received insufficient research attention despite clear evidence of potential health impacts.¹²²

Following the current CDC schedule, infants receive approximately 3,235 micrograms of aluminum from vaccines by their first birthday.¹²³ This represents a dramatic increase from historical levels and far exceeds exposure from other sources during the same period.

DIETARY ALUMINUM EXPOSURE COMPARISON (FIRST YEAR OF LIFE)

SOURCE	TOTAL EXPOSURE	ABSORPTION RATE	ABSORBED AMOUNT
Breast milk	7 mg	0.1-0.78%	7-55 µg
Standard formula	38 mg	0.1-0.78%	38-296 µg
Soy formula	117 mg	0.1-0.78%	117-913 µg

Sources: Robert J. Mitkus, David B. King, Maureen A. Hess, Richard A. Forshee, and Mark O. Walderhaug. "Updated aluminum pharmacokinetics following infant exposures through diet and vaccination." *Vaccine*, Nov. 2011, Vol. 29(51):9538-9543. <https://www.sciencedirect.com/science/article/abs/pii/S0264410X11015799>; Agency for Toxic Substances and Disease Registry. "Toxicological Profile for Aluminum." *U.S. Department of Health and Human Services*, Sept. 2008. <https://www.atsdr.cdc.gov/toxprofiles/tp22.pdf>.

The route of administration creates additional concerns that dietary comparisons obscure. Aluminum absorbed from food faces the protective barriers of the digestive system, with absorption rates between 0.1% and 0.78%. Aluminum injected directly into muscle tissue bypasses these protections entirely. The primary driver of aluminum exposure in infants and young children in the United States is vaccines. Dietary factors don't even come close.

THE CDC'S OWN STUDY: EVIDENCE FOUND AND DISMISSED

In 2022, researchers funded by the CDC conducted one of the largest vaccine safety studies ever undertaken, examining aluminum adjuvant exposure and health outcomes in 326,991 children. The study found a statistically significant association between cumulative aluminum exposure from vaccines before children 24 months old and persistent asthma between children 24 and 59 months old.¹²⁴

Children in the highest aluminum exposure quartile showed a 26% higher asthma rate compared to those in the lowest quartile. This finding deserves emphasis because the study size requires substantial effect sizes to detect health associations; the statistical power needed to identify signals among 326,991 children makes this association extraordinarily robust; and the study was funded by the CDC itself, conducted by mainstream researchers, and published in a peer-reviewed journal.

Despite the study's size, funding source, and clear statistical significance, CDC officials indicated that "further investigation would be needed" before considering policy changes. The absence of systematic follow-up research represents a troubling pattern: When health agencies' own studies identify potential safety signals, the response should be an immediate and thorough investigation, not bureaucratic delay.

How should this be interpreted? When a large study fails to find a statistically significant association, like the studies on thimerosal and autism, this doesn't rule out the potential for individual harm. But when studies like the CDC's study on aluminum and asthma do find a population-level association, it means that harm at the individual level isn't just possible; it's certain.

Why wouldn't there be a follow-up? One possible explanation links back to the expansion of the pediatric vaccine schedule. The reason that aluminum is added to vaccines is to provide a kickstart. Aluminum boosts the efficacy of vaccines and makes their benefits more long-lasting. Removing aluminum from vaccines would mean that, to keep with the current pediatric vaccine schedule, the number and frequency of injections would have to increase dramatically.

The U.S. has a vaccine schedule that is up to twice as large as most other developed countries. If aluminum were pulled from vaccines, there'd be even more shots,

and the already strained system would break down. The size of the schedule has become its own justification for continuing to use an additive with real evidence of harm.

Aluminum at Lower Doses: The Danish Results

While a follow-up study of the CDC's results has yet to be completed, recently published international research has provided additional information on this topic. A major nationwide cohort study from Denmark evaluated the potential association between cumulative aluminum exposure from early childhood vaccinations and the development of autoimmune, allergic, or neurodevelopmental disorders.¹²⁵ Using registry data from over 1.2 million children born between 1997 and 2018, the authors found no statistically significant association between aluminum exposure from vaccines and any of the 50 chronic conditions analyzed.

In its discussion section, the study referenced the CDC article that had found an association between aluminum exposure and increased asthma risk, but failed to contextualize or quantify the substantial differences between the Danish and U.S. vaccine schedules that explain, at least in part, if not all, of the reasons for the differences in results.¹²⁶ Danish children receive far fewer aluminum-adsorbed vaccines in early childhood, typically receiving three doses in the diphtheria/tetanus/pertussis (DTaP) series—all of which contain aluminum, and neither hepatitis A nor hepatitis B vaccines are on the universal schedule.¹²⁷ In contrast, children in the United States receive five doses of DTaP instead of three, and routinely receive additional aluminum-containing vaccines such as hepatitis A and B.

This leads to dramatically higher cumulative aluminum exposure in the U.S., estimated at approximately 5,000 micrograms by age five, compared to approximately 3,000 micrograms in the Danish cohort.¹²⁸ The omission of this magnitude of difference represents a significant limitation in applying the Danish findings to U.S. vaccine policy discussions. Aluminum has a well-established nonlinear dose-response relationship for toxicity. It acts like a hockey stick; at low doses little to no harm has been observed in animal studies, but when a threshold level is reached, toxic effects increase exponentially. A very reasonable conclusion from this study is that the relatively low doses of aluminum in the Danish schedule—among the lowest in any pediatric vaccine schedule globally—

are not associated with chronic disease because they never reach the threshold. Put another way, the low doses of aluminum in the Danish schedule occur on the blade of the hockey stick, while the higher doses seen in the U.S. likely fall on the shaft. In conclusion, these findings lend support to efforts aimed at reducing aluminum exposure in U.S. pediatric vaccination schedules.

The Double Standard in Clinical Practice

A fundamental principle of medicine taught to clinicians is this: When a patient experiences an acute medical issue or change in condition, look at the medication list. This represents standard clinical practice across medicine—except, it seems, when it comes to vaccines.

In nearly every medical context, temporal relationships between interventions and subsequent health changes warrant serious consideration. A patient who develops a rash after starting a new antibiotic would never hear “that’s just coincidental.” A child who experiences stomach pain after beginning a new ADHD medication would not be told their symptoms have nothing to do with the recent prescription. Yet parents who observe concerning changes in their children following vaccination routinely face dismissal of their observations as mere coincidence or confirmation bias.

STANDARD MEDICAL PRACTICE VS. VACCINE EXCEPTIONS	
STANDARD PRACTICE	VACCINE EXCEPTION
Patient develops rash after starting new antibiotic ➔ investigate potential drug reaction	Child experiences behavioral changes after vaccination ➔ “just coincidental”
Adult reports muscle pain after beginning statin therapy ➔ evaluate for drug-induced myopathy	Parent reports seizures following immunization ➔ “might have happened anyway”
Suspected reactions to medications are meticulously recorded in medical charts	Physicians frequently exhibit reluctance to document potential vaccine reactions

This double standard extends to documentation practices. Suspected reactions to medications are meticulously recorded in medical charts, often leading to lifelong alerts in electronic health records. But physicians frequently exhibit reluctance to document potential vaccine reactions, sometimes out of concern for contributing to “vaccine hesitancy” or facing judgment from colleagues.

This documentation gap creates a self-reinforcing system where adverse events go unrecorded, leading to the circular conclusion that they must be rare. This approach not only is a disservice to the affected families but ultimately undermines trust in the entire vaccination program.

THE INFORMATION REVOLUTION AND PARENTAL DECISION-MAKING

These evidence evaluation problems have emerged alongside a transformation in how families access and evaluate medical information. The landscape of healthcare decision-making has been transformed by the democratization of information access, yet vaccination policy continues to operate under assumptions that reflect an outdated model of medical authority.

Parents today access the same primary scientific literature as healthcare providers, connect with global communities of practice, and evaluate interventions through frameworks that extend beyond simple compliance with professional recommendations. This evolution represents adaptation to an information environment that has democratized access to knowledge while simultaneously revealing the limitations and inconsistencies in expert recommendations.

The Failure of Gatekeeper Models

For most of the twentieth century, medical knowledge operated within a gatekeeper model where physicians and public health officials served as primary information conduits. The internet disrupted this model entirely, collapsing the traditional timeline of medical knowledge dissemination from decades to hours. The landscape of expertise has undergone an irrevocable

shift, not just in medicine, but across all professions. While the frustration with this shift is palpable among public health leadership, they would be wise not to dismiss it.

Current vaccination policy assumes parents will accept expert recommendations without independent verification—an assumption that has become increasingly untenable. When parents discover through their own research that vaccines promoted for “community benefit” provide primarily individual protection, they reasonably question other official health communications.

Current Trends and Their Implications

For the 2023-24 school year, vaccination exemptions among kindergartners in the United States reached a record high of 3.3%, representing approximately 127,000 children exempt from one or more required vaccines.¹²⁹ Coverage for critical vaccines has fallen below optimal thresholds:

VACCINE	2023-24 COVERAGE	CHANGE FROM PREVIOUS YEAR
MMR	92.7%	↓ from 93.1%
DTaP	92.3%	↓ from 92.7%
Polio	92.6%	↓ from 93.1%
Varicella	92.3%	↓ from 92.8%

These declines affect all socioeconomic groups and represent a significant departure from the coverage maintained before recent policy conflicts. The data suggest that coercive approaches may undermine their own objectives when applied to populations with access to alternative information sources and institutional arrangements.

The Sophistication of Parental Analysis

Research reveals that parental vaccine decision-making stems from specific, often scientifically grounded concerns rather than wholesale rejection of vaccination concepts. Safety concerns represent the most frequently cited reason for vaccine hesitancy, with parents consistently expressing a desire for more information about vaccines and their effects on children. Healthcare provider communication and the quality of that dialogue prove critical to vaccination acceptance. Even among broadly supportive parents, concerns about vaccine necessity and timing reflect thoughtful consideration rather than blanket opposition.¹³⁰

Parents prove remarkably capable of understanding complex distinctions when provided with accurate information. They can readily grasp that measles vaccination creates fundamentally different community protection than tetanus vaccination, which prevents individual environmental exposure with no person-to-person transmission. When these distinctions are acknowledged rather than obscured, families can make more informed decisions about which vaccines provide direct benefits to their children versus those serving broader societal goals.

The Counterproductive Nature of Current Approaches

Current policy creates a false binary: accept every vaccine on the recommended schedule exactly when recommended, or be labeled “vaccine hesitant” or “non-compliant.” This rigid categorization makes no distinction between parents seeking minor modifications to timing and those rejecting all vaccines outright.

A child who has received protection against measles, mumps, rubella, diphtheria, and pertussis—all Category 1 vaccines with genuine community protection implications—falls into the same statistical category as a child who has received no vaccines whatsoever if they haven’t completed the hepatitis B series. This false equivalence transforms nuanced medical conversations into battles of allegiance.

The medicalization of dissent—characterizing parental questions as “vaccine hesitancy” requiring treatment rather than engagement—serves institutional convenience while undermining doctor-patient relationships. This approach prevents meaningful engagement with substantive concerns about policy implementation, timing, or the necessity of vaccines for diseases with specific transmission patterns.

A PATH FORWARD:

ALIGNING SCIENCE, BIOLOGY, AND PUBLIC TRUST

Current vaccination policy increasingly undermines its own objectives by treating all vaccines as equivalent community protection measures, dismissing legitimate concerns, and operating under information models that technology rendered obsolete decades ago. This system drives thoughtful families away from the very interventions most critical for public health.

The solution requires acknowledging that vaccination's remarkable success demands more sophisticated policy approaches that distinguish between vaccines serving different functions while respecting the intelligence of families making healthcare decisions.

Evidence-Based Refinements

International comparisons demonstrate that excellent disease control is achievable through more nuanced approaches than current maximalist strategies. Countries like Sweden achieve higher vaccination rates for critical vaccines through voluntary programs that emphasize education and differentiation rather than universal mandates and false equivalence.

The three-category framework provides a foundation for such refinements. By distinguishing between vaccines that genuinely require community participation (Category 1) and those that primarily protect individuals (Category 3), policy can focus resources where they matter most while addressing legitimate concerns about timing, necessity, and individual risk assessment.

Developmental Alignment

The developmental patterns in children should influence vaccination policy establishment rather than administrative convenience. A four-year-old possesses a more mature immune system that produces more powerful and enduring immune responses than a 12-month-old. Adolescent immune responses approach adult levels of strength and durability, resulting in protection that persists during periods of actual exposure risk.

Research demonstrates that vaccination at older ages produces stronger antibody responses and longer-lasting immunity compared to infant vaccination. Early vaccine administration remains necessary for infections that pose serious risks to infants, but the developmental perspective supports more sophisticated timing strategies for diseases that primarily threaten older children or adults.

Our current schedule is front-loaded to infants and young children. By 12 months of age, most children have enough maturity in their immune systems to respond to live vaccines such as the MMR combination, which is why the U.S. and many other countries give the first dose then. But by 15 months, even more children will have the ability to generate a robust immune response. This is especially true for those who were born significantly premature or have other causes of delayed immune development. Denmark and Norway acknowledge this by scheduling the initiation of the series at 15 months; France has a baseline start at 12 months, but commonly allows catch-up with the schedule at 15 or 18 months; Sweden begins the series at 18 months. These delayed and flexible approaches align with differences in immune development and help build trust with parents.

Evidence suggests that schedule modifications aligned with immune system development and actual disease risk patterns could reduce aluminum exposure during critical developmental windows while maintaining protection when it is needed. Moving hepatitis B vaccination to adolescence, for example, would provide immunity during the period of actual risk exposure while reducing early childhood aluminum burden by approximately 18%.

Single-Vaccine Alternatives

Historically, the option of single-antigen vaccines was available to address children who were vaccinated for core diseases with an alternative schedule. This strategy

worked because it recognized that even among the Category 1 vaccines—which cover diseases that are casually communicable and require high percentages of participation to be effective—there are differences in the coverage rates necessary for herd immunity. The current measles-mumps-rubella (MMR) vaccine combination highlights these differences. Measles has a herd immunity threshold of 95%. It is possible that a single antigen strategy—focusing first on measles, with subsequent vaccinations for mumps and rubella—could lead to lower rates of uptake for mumps and rubella, but their herd immunity requirements are much lower (80-85%).¹³¹

Combination vaccines originally were meant to minimize discomfort, but since 1986, they have had a different role. With 17 different vaccines, many of them frontloaded in early infant and toddler timeframes, combination vaccines now have a circular logic. They are necessary in the service of completing a bloated schedule, and instead of minimizing the number of shots children get, they have become a way to justify more and more additions to the schedule.

There are parents who will have a greater willingness to participate fully in the schedule if their children were offered the option to receive vaccines in a more measured way. Giving vaccines as single antigen shots is one way of achieving this. Parents are less likely to see their infants and toddlers as being overloaded with multiple different antigens, and teasing out adverse events would be more straightforward if only a single vaccine were delivered at a given visit.

From a practical standpoint, single antigen vaccines are not available for the Category 1 vaccines (with the exception of the varicella vaccine for chicken pox). While single antigen options could part of rebuilding trust, making these available again (the single options for the MMR components were last manufactured in 2009), would require several steps—the identification of a reliable market (at least 200,000 children each year), FDA action, and updated safety studies all would need to be in place before production could resume, a process that likely would take three to five years.¹³²

The Necessity of Mandates

When we consider vaccine mandates, it's important to remember that however well-intended, any mandate represents both a loss of bodily autonomy for a child and a loss of parental authority to make decisions about what they consider to be

in their child's best interest. As we weigh the values of individual rights versus the collective good, multiple factors must be considered:

- How contagious is the disease? Is it possible for vulnerable populations to avoid exposure?
- What are the consequences of infection versus the potential harms of the vaccine to the individual (especially if immunocompromised or at greater risk of an adverse effect)? Is the disease likely to be mild, or are death and major disability risks high?
- Is the mandated time frame logically aligned with immune development and the natural onset of the disease the vaccine targets?

When a vaccine addresses a contagious disease that is easily communicable, when the risk of death or disability from infection is high, and the proposed interventions are well-aligned with the child's development and the usual onset of the disease, inclusion in the schedule has greater justification. But when these standards are not met, and especially when non-medical drivers, such as administrative convenience or economics, are the justification, we should pause and consider whether or not mandates are justifiable. At a minimum, we should always be transparent and forthcoming about the reasons that underlie these decisions.

Our current system has its founding in an era before electronic health records, before health information exchanges, and before large language models were available. Arguments based on administrative convenience ignore these advances and their potential role in vaccine administration decisions.

Research Imperatives

This analysis reveals profound gaps in understanding of the cumulative effects of the dramatically expanded vaccination schedule. The Institute of Medicine's acknowledgment that "studies designed to examine the long-term effects of the timing and number of immunizations have not been conducted" represents an extraordinary admission about interventions administered to millions of children annually.

Future research priorities should include:

- Comparative studies of health outcomes across different vaccination schedules
- Systematic investigation of cumulative effects
- Research on optimal timing based on immune system development
- Honest acknowledgment of limitations in current safety monitoring systems

Transparency and Trust

The path forward requires abandoning rhetorical convenience in favor of honest communication about what different vaccines accomplish. Parents can and do understand that measles vaccination creates fundamentally different community protection than hepatitis B vaccination. When these distinctions are acknowledged rather than obscured, families can make informed decisions about which vaccines provide direct benefits to their children versus those serving broader societal goals.

Honest acknowledgment of what different vaccines accomplish builds more sustainable foundations for vaccination programs than overstating the collective benefits of particular vaccines and the absolute need for universal participation. When parents discover through research that vaccines promoted for “community benefit” provide primarily individual protection, they reasonably question other official health communications.

The Choice Before Us

We face a clear choice: continue defending an increasingly untenable status quo that treats complex medical decisions as matters of compliance or evolve toward approaches that respect both the science of vaccination and the intelligence of families. The former leads toward further polarization and even greater drops in coverage for vaccines that genuinely require community participation. The latter offers the possibility of rebuilding vaccination programs on more sustainable foundations.

By focusing on vaccines that truly require universal vaccination and identifying opportunities for flexibility, we can begin the process of rebuilding trust and can create new vaccination programs on a foundation of scientific precision rather than administrative convenience. This approach would potentially increase overall vaccination rates for the most critical vaccines by reducing all-or-nothing decision-making while respecting the complex realities of how families evaluate medical interventions.

CONCLUSION

Vaccination remains one of medicine's most important contributions to public health. It is precisely because of its importance that we must approach vaccination policy with the sophistication it deserves—acknowledging both its remarkable achievements and the opportunities for evidence-based refinement that could restore public trust and optimize health outcomes for all children.

The way forward requires the courage to confront the limitations of our current approach and the willingness to implement reforms rooted in science, transparency, and partnership with families. Our one-size-fits-all mandate model has become counterproductive—treating vaccines with different purposes and transmission dynamics as if they serve identical public health functions erodes trust in the very tools most critical for community protection.

The proposed three-category framework offers a way to recalibrate. By focusing considerations for mandates on Category 1 vaccines—those that prevent highly contagious and immediately dangerous diseases—and allowing greater flexibility for vaccines that provide primarily individual protection, we align policy with both scientific evidence and ethical responsibility. For all vaccines, consideration of child immune development and the natural history of disease provide opportunities for thoughtful adjustments to their timing in the recommended schedule.

This shift would not weaken vaccine programs; it would strengthen them. Grounding public policy in medical precision, not administrative convenience, creates space for informed partnerships between providers and parents—relationships that ultimately determine the success of any public health effort.

The choice before us is clear: continue defending increasingly rigid policies that have broken public trust and often run counter to the evidence, or evolve toward an approach that respects both the power of vaccines and the wisdom of families. The future of vaccination programs—and the children they are meant to protect—depends on the path we choose.

ABOUT THE AUTHOR



Monique Yohanan, MD, MPH, received her medical degree from Brown University and Master of Public Health from Johns Hopkins University. She completed postgraduate training at Harvard and Stanford and has held faculty positions at UCSF and Stanford. Dr. Yohanan has nearly 20 years of experience in evidence-based medicine and clinical guideline development, previously serving as medical director for a Medicaid plan and currently as chief medical officer for an AI healthcare company. She is a senior fellow at Independent Women and lives in California with her husband and son.

ENDNOTES

1. C. M. C. Rodrigues and S. A. Plotkin. "Impact of Vaccines; Health, Economic and Social Perspectives." *Frontiers in Microbiology*, Jul. 13, 2020. Vol. 11:1526. <https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2020.01526/full>; Andrew J Shattock, et al. "Contribution of Vaccination to Improved Survival and Health: Modelling 50 years of the Expanded Programme on Immunization." *The Lancet*, May 25, 2024, Vol. 403(10441): 2307-2316. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(24\)00850-X/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00850-X/fulltext).
2. "Measles Cases and Outbreaks." *Centers for Disease Control and Prevention*, Jul. 2, 2024. <https://www.cdc.gov/measles/data-research/index.html>.
3. Rane Seither, et al. "Coverage with Selected Vaccines and Exemption Rates Among Children in Kindergarten—United States, 2023-24 School Year." *Morbidity and Mortality Weekly Report*, Oct. 17, 2024. Vol. 73(41):925-932. <https://www.cdc.gov/mmwr/volumes/73/wr/mm7341a3.htm>; Edwards Erika. "CDC Reports Highest Childhood Vaccine Exemption Rate Ever in the U.S." *NBC News*, Nov. 15, 2023. <https://www.nbcnews.com/health/health-news/cdc-reports-highest-childhood-vaccine-exemption-rate-ever-rcna124363>.
4. Douglas J. Opel, et al. "Use of Alternative Childhood Immunization Schedules in King County, Washington, USA." *Vaccine*, 2013. Vol. 31(42):4699-4701. <https://pubmed.ncbi.nlm.nih.gov/23981431/>; Steve G. Robison, et al. "Frequency of Alternative Immunization Schedule use in a Metropolitan Area." *Pediatrics*, Jul. 2012. Vol. 130(1):32-38. <https://pubmed.ncbi.nlm.nih.gov/22711719/>.
5. Institute of Medicine. "The Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence, and Future Studies." *National Academies Press*, Mar. 27, 2013. <https://www.ncbi.nlm.nih.gov/books/NBK206938/>; Peter Doshi, et al. "Visualising Childhood Vaccination Schedules Across G8 Countries." *BMJ*, Nov. 15, 2015. Vol. 351(h5966). <https://pubmed.ncbi.nlm.nih.gov/26568637/>.
6. Peter Doshi, et al. "Visualising Childhood Vaccination Schedules Across G8 Countries." *BMJ*, Nov. 15, 2015. Vol. 351(h5966). <https://pubmed.ncbi.nlm.nih.gov/26568637/>.
7. The College of Physicians of Philadelphia. "The Development of the Immunization Schedule." *History of Vaccines*, accessed July 23, 2025. <https://historyofvaccines.org/getting-vaccinated/vaccines-children/development-immunization-schedule/>.
8. Vaccine Education Center. "Vaccine history: Developments by Year." *Children's Hospital of Philadelphia*, accessed July 23, 2025. <https://www.chop.edu/vaccine-education-center/science-history/vaccine-history/developments-by-year>.
9. "Childhood Vaccine Schedule." *Cleveland Clinic*, Sept. 12, 2024. <https://my.clevelandclinic.org/health/articles/11288-childhood-immunization-schedule>.
10. Advisory Committee on Immunization Practices. "ACIP Recommendations." *Centers for Disease Control and Prevention*, May 15, 2025. <https://www.cdc.gov/acip/vaccine-recommendations/index.html>.
11. Sean T. O'Leary, et al. "Policies Among US Pediatricians for Dismissing Patients for Delaying or Refusing Vaccination." *JAMA Pediatrics*, Sept. 15, 2020. Vol. 174(10):1027-1028. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7492908/>.
12. Institute of Medicine. "The Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence, and Future Studies." *National Academies Press*, Mar. 27, 2013. <https://www.ncbi.nlm.nih.gov/books/NBK206938/>; "Vaccine Scheduler: Vaccine Schedules in all Countries in the EU/EEA." *European Centre for Disease Prevention and Control*, accessed July 23, 2025. <https://vaccine-schedule.ecdc.europa.eu/>.

13. "Measles immunization in the US." *National Foundation for Infectious Diseases*, Jun. 9, 2023. <https://www.nfid.org/measles-immunization-in-the-us/>.
14. "Vaccination Register and Vaccination Coverage." *The Public Health Agency of Sweden*, Mar. 10 2023. <https://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/communicable-disease-control/vaccinations/vaccination-register-and-vaccination-coverage/>; "Japan Measles Immunization Rate." *The GlobalEconomy.com*, https://www.theglobaleconomy.com/Japan/measles_immunization_rate/; Jill Rosen. "New Data Shows MMR Vaccination Rate Decline Across the U.S." *The Johns Hopkins University Hub*, Jun. 3, 2025. <https://hub.jhu.edu/2025/06/03/united-states-measles-vaccination-rate-declines/>.
15. "Your Newborn Baby." *NHS*, accessed July 23, 2025. <https://www.nhs.uk/common-health-questions/childrens-health/how-long-do-babies-carry-their-mothers-immunity/>.
16. Eleanor C. Simmes, et al. "Understanding Early-life Adaptive Immunity to Guide Interventions for Pediatric Health." *Frontiers in Immunology*, Jan. 21, 2021. Vol. 11. <https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.595297/full>.
17. Shadi N. Malaeb, et al. "Core Concepts: Development of the Blood-brain Barrier." *Neo Reviews*, Apr. 1, 2012. Vol. 13(4). <https://publications.aap.org/neoreviews/article/13/4/e241/88407/Core-ConceptsDevelopment-of-the-Blood-Brain>.
18. Andrew J. Pollard, et al. "A Guide to Vaccinology: From Basic Principles to New Developments." *Nature Reviews Immunology*, Feb. 2021, Vol. 21:83-100. <https://www.nature.com/articles/s41577-020-00479-7>.
19. Zsófia Bugya, et al. "Multiple Levels of Immunological Memory and Their Association with Vaccination." *Vaccines*, Feb. 19, 2021, 9(2):174. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7922266/>.
20. Gaston De Serres, et al. "Higher Risk of Measles When the First Dose of a 2-dose Schedule of Measles Vaccine is given at 12-14 Months versus 15 Months of Age." *Clinical Infectious Diseases*, Aug. 1, 2012. Vol. 55(3):394-402. <https://academic.oup.com/cid/article-abstract/55/3/394/614245>.
21. Sabra L. Klein and Rosemary Morgan. "The Impact of Sex and Gender on Immunotherapy Outcomes." *Biology of Sex Differences*, May 4, 2020. <https://bsd.biomedcentral.com/articles/10.1186/s13293-020-00301-y>.
22. Sabra L. Klein and Rosemary Morgan. "Sex Differences in Immune Responses." *Nature Reviews Immunology*, Aug. 22, 2016. <https://www.nature.com/articles/nri.2016.90>.
23. Sabra L. Klein, et al. "Sex-based Differences in Immune Function and Responses to Vaccination." *Trans R Soc Trop Med Hyg*, Jan. 7, 2015, Vol. 109(1):9-15. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4447843/>.
24. Mélanie Souyris, et al. "TLR7 Escapes X Chromosome Inactivation in Immune Cells." *Science Immunology*, Jan. 26, 2018. Vol. 3(19). <https://www.science.org/doi/10.1126/sciimmunol.aap8855>.
25. Benjamin Knudsen and Vinay Prasad. "PMC: Systematic Review of Myocarditis Rates (39 cases per 100,000 in males 12-17)." *Eur J Clin Invest*, Jan 3, 2023. e13947 <https://pubmed.ncbi.nlm.nih.gov/36576362/>; Martina Patone, et al. "Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex." *Circulation*, Aug. 22, 2022. Vol. 146(10). <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.059970>.
26. Chloe Taylor. "Nordic Countries are Restricting the Use of Moderna's Covid Vaccine. Here's Why." *CNBC*, Oct. 8, 2021. <https://www.cnn.com/amp/2021/10/08/nordic-countries-are-restricting-the-use-of-modernas-covid-vaccine.html>.
27. Terence T. Lao. "Long-term Persistence of Immunity After Hepatitis B Vaccination: Is This Substantiated by the Literature?" *Hum Vaccin Immunother*, Mar. 1, 2017, Vol. 13(4):918-920. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5404367/>; Institute of Medicine. "Immunization Safety Review: Multiple Immunizations and Immune Dysfunction." *National Academies Press*, 2002. <https://www.ncbi.nlm.nih.gov/books/NBK220494/>; Shixin Shen and Vinita Dubey. "Addressing Vaccine Hesitancy: Clinical Guidance for Primary Care Physicians Working with Parents." *Can Fam Physician*, Mar. 2019, Vol. 65(3):175-181. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6515949/>.
28. G.L. Armstrong, et al. "Trends in Infectious Disease Mortality in the United States During the 20th Century." *JAMA*, Jan. 6, 1999. Vol. 281(1):61-6. <https://pubmed.ncbi.nlm.nih.gov/9892452/>; Brian Greenwood. "The Contribution of Vaccination

- to Global Health: Past, Present and Future." *Philos Trans R Soc Lond B Biol Sci*, Jun. 19, 2014, Vol. 369(1645):20130433. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4024226/>.
29. Theodore H Tulchinsky. "John Snow, Cholera, the Broad Street Pump; Waterborne Diseases Then and Now." *Case Studies in Public Health*, Mar. 30, 2018, Vol. 30:77–99. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7150208/>;
 - John F. Murray. "A Century of Tuberculosis." *American Journal of Respiratory and Critical Care Medicine*, Mar. 2, 2004, Vol. 169(11):1182–6. <https://www.atsjournals.org/doi/full/10.1164/rccm.200402-140oe>.
 30. Lien Anh Ha Do and Kim Mulholland. "Measles 2025." *New England Journal of Medicine*, Jun. 25, 2025. <https://www.nejm.org/doi/full/10.1056/NEJMra2504516>.
 31. F. Estivariz, et al. "Chapter 18: Poliomyelitis." *Centers for Disease Control and Prevention*, May 1, 2024. <https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-18-poliomyelitis.html>.
 32. Charlene M. C. Rodrigues and Stanley A. Plotkin. "Impact of Vaccines; Health, Economic and Social Perspectives." *Front Microbiol*, Jul. 13, 2020, Vol.11:1526. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371956/>.
 33. Faculty of Public Health. "Definitions in Disease Control." *Health Knowledge*, accessed Jul. 23, 2025. <https://www.healthknowledge.org.uk/public-health-textbook/disease-causation-diagnostic/2g-communicable-disease/definitions-disease-control>.
 34. Pedro Plans-Rubió. "Evaluation of the Establishment of Herd Immunity in the Population by Means of Serological Surveys and Vaccination Coverage." *Hum Vaccin Immunother*, Feb. 2012. Vol. 8(2):184–8. <https://pubmed.ncbi.nlm.nih.gov/22426372/>.
 35. Anindita N. Issa, et al. "Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger—United States, 2025." *Morbidity and Mortality Weekly Report*, Jan. 16, 2025. Vol. 74(2):26–29. <https://www.cdc.gov/mmwr/volumes/74/wr/mm7402a2.htm>; Pedro Plans-Rubió. "Evaluation of the Establishment of Herd Immunity in the Population by Means of Serological Surveys and Vaccination Coverage." *Hum Vaccin Immunother.*, Feb. 2012, Vol. 8(2):184–8. <https://pubmed.ncbi.nlm.nih.gov/22426372/>.
 36. Pandora Dewan. "Science Fact Check: Was the Definition of COVID Vaccine 'Changed'?" *Newsweek*, Oct. 4, 2024. <https://www.newsweek.com/science-fact-check-definition-vaccine-cdc-1964107>.
 37. Pedro Plans-Rubió "Evaluation of the establishment of herd immunity in the population by means of serological surveys and vaccination coverage." *Hum Vaccin Immunother*, Feb. 1, 2012, 8(2):184–8. <https://www.tandfonline.com/doi/full/10.4161/hv.18444>.
 38. "Nearly 40 Million Children are Dangerously Susceptible to Growing Measles Threat." *World Health Organization*, Nov. 23, 2022. <https://www.who.int/news/item/23-11-2022-nearly-40-million-children-are-dangerously-susceptible-to-growing-measles-threat>.
 39. While all diseases in this category fit the general characteristics necessary for herd immunity to be applicable, varicella highlights that breaks in childhood transmission have the potential to have unintended consequences. Prior to universal vaccination, varicella infection (chicken pox), was rarely fatal, but it did have a population-level benefit. Adults who were re-exposed to chicken pox had a decreased likelihood of herpes-zoster (shingles). So while the varicella vaccine has been associated with a decrease in morbidity and mortality in children, there is evidence that the burden may have been shifted to older adults in the form of shingles infection. M Brisson, N J Gay, W J Edmunds, and N J Andrews. "Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox." *Vaccine*, Jun. 7, 2002, Vol. 20(19–20):2500–7. <https://pubmed.ncbi.nlm.nih.gov/12057605/>.
 40. Beth Temple, et al. "Efficacy Against Pneumococcal Carriage and the Immunogenicity of Reduced-dose (0 + 1 and 1 + 1) PCV10 and PCV13 Schedules in Ho Chi Minh City, Viet Nam: A Parallel, Single-blind, Randomised Controlled Trial." *The Lancet Infectious Diseases*, Aug. 2023. Vol. 23(8). [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(23\)00061-0/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00061-0/fulltext); Andrew Terranella, et al. "Meningococcal Conjugate Vaccines: Optimizing Global Impact." *Infect Drug Resist*, Sept. 21, 2011. Vol. 4:161–169. <https://pmc.ncbi.nlm.nih.gov/articles/PMC3215346/>; A. K. Takala, et al. "Reduction of Oropharyngeal Carriage of

- Haemophilus Influenzae Type B (Hib) in Children Immunized with an Hib Conjugate Vaccine." *Journal of Infectious Diseases*, Nov. 1991. Vol. 164(5):982-6. <https://pubmed.ncbi.nlm.nih.gov/1940479/>.
41. "Tetanus: Causes and Transmission." *Centers for Disease Control and Prevention*, Jun. 10, 2024. <https://www.cdc.gov/tetanus/causes/index.html>.
42. Ryan E. Malosh, et al. "Effectiveness of Influenza Vaccines in the HIVE Household Cohort Over 8 Years: Is There Evidence of Indirect Protection?" *Clinical Infectious Diseases*, Oct. 1, 2021. Vol. 73(7). <https://academic.oup.com/cid/article/73/7/1248/6265275>; Anika Singanayagam, et al. "Community Transmission and Viral Load Kinetics of the SARS-CoV-2 delta (B.1.617.2) Variant in Vaccinated and Unvaccinated Individuals in the UK: A Prospective, Longitudinal, Cohort Study." *The Lancet Infectious Diseases*, Feb. 2022. Vol. 22(2). [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(21\)00648-4/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00648-4/fulltext).
43. "Hepatitis: Preventing Mother-to-child Transmission of the Hepatitis B Virus." *World Health Organization*, Jul. 27, 2024. <https://www.who.int/news-room/questions-and-answers/item/hepatitis-preventing-mother-to-child-transmission-of-the-hepatitis-b-virus>.
44. Venetia Qendri, et al. "Who Will Benefit From Expanding HPV Vaccination Programs to Boys?" *Journal of the National Cancer Institute*, Dec. 21, 2018, Vol. 2(4). <https://pmc.ncbi.nlm.nih.gov/articles/PMC6649811/>.
45. "Rotavirus Vaccination." *Centers for Disease Control and Prevention*, Jul. 19, 2024. <https://www.cdc.gov/rotavirus/vaccines/index.html>.
46. Trudy V. Murphy, et al. "Progress Toward Eliminating Hepatitis A Disease in the United States." *Morbidity and Mortality Weekly Report*, Feb. 12, 2016, Vol. 65(1): 29-41. <https://www.cdc.gov/mmwr/volumes/65/su/su6501a6.htm>; Megan Hofmeister, et al. "Preventable Deaths During Widespread Community Hepatitis A Outbreaks—United States, 2016–2022." *Morbidity and Mortality Weekly Report*, Oct. 20, 2023. Vol. 72(42): 1128–1133. <https://www.cdc.gov/mmwr/volumes/72/wr/mm7242a1.htm>.
47. "Inactivated Poliovirus Vaccine." *Global Polio Eradication Initiative*, accessed Jul. 23, 2025. <https://polioeradication.org/about-polio/the-vaccines/ipv/>.
48. "Oral Polio Vaccine." *Global Polio Eradication Initiative*, accessed on Jul. 23, 2025. <https://polioeradication.org/about-polio/the-vaccines/opv/>.
49. Concepcion F. Estivariz, et al. "Chapter 18: Poliomyelitis." *Centers for Disease Control and Prevention*, May 1, 2024. <https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-18-poliomyelitis.html>.
50. Vaccine Education Center. "Polio: The Disease & Vaccines." *Children's Hospital of Philadelphia*, accessed Jul. 23, 2025. <https://www.chop.edu/vaccine-education-center/vaccine-details/polio-vaccine>.
51. *Jacobson v. Massachusetts*, 197 U.S. 11 (1905). <https://supreme.justia.com/cases/federal/us/197/11/>.
52. Wendy E. Parmet, et al. "Individual Rights versus the Public's Health—100 Years after *Jacobson v. Massachusetts*." *N Engl J Med*, Feb. 17, 2005. Vol. 352(7):652-654. <https://www.nejm.org/doi/abs/10.1056/NEJMp048209>.
53. "How Smallpox Spreads." *Centers for Disease Control and Prevention*, Oct. 22, 2024. <https://www.cdc.gov/smallpox/causes/index.html>; Sophie Ochmann, et al. "Smallpox: Humanity Eradicated This Infectious Disease Globally. How was This Possible?" *Our World in Data*, Jun. 2018. <https://ourworldindata.org/smallpox>.
54. *Jacobson v. Massachusetts*, 197 U.S. 11 (1905). <https://supreme.justia.com/cases/federal/us/197/11/>.
55. David Jones and Stefan Helmreich. "A History of Herd Immunity." *The Lancet*, Sept. 19, 2020, Vol. 396(10254):810-811. <https://www.thelancet.com/journals/lancet/article/PIIS0140-67362031924-3/fulltext>.
56. Tae Hyong Kim, Jennie Johnstone and Mark Loeb. "Vaccine Herd Effect." *Scand J Infect Dis*, May 2011. Vol. 23;43(9):683–689. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171704/>.
57. Lawrence O. Gostin. "*Jacobson v Massachusetts* at 100 Years: Police Power and Civil Liberties in Tension." *American Journal of Public Health*, Apr. 2005. Vol. 95(4): 576-581. <https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2004.055152>.
58. *Zucht v. King*, 260 U.S. 174 (1922). <https://supreme.justia.com/cases/federal/us/260/174/>.
59. Institute of Medicine. "The Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence, and Future Studies." *National Academies Press*, Mar. 27, 2013. <https://www.ncbi.nlm.nih.gov/books/NBK206938>.

60. Heather Tomlinson. "The Impact of Non-Medical Vaccine Exemptions on Childhood Vaccination Rates." *Association of State and Territorial Health Officials*, Mar. 16, 2023. <https://www.astho.org/communications/blog/impact-of-non-medical-vaccine-exemptions-on-childhood-vaccination-rates/>.
61. "HEDIS Measures & Billing Codes." *Health Net*, Jul. 9, 2025. https://www.healthnet.com/content/healthnet/en_us/providers/working-with-hn/hedis-measure-specifications.html.
62. Aylin Sertkaya. "New Estimates of the Cost of Preventive Vaccine Development and Potential Implications from the COVID-19 Pandemic." *Office of the Assistant Secretary for Planning and Evaluation*, Jan. 8, 2025. <https://aspe.hhs.gov/reports/cost-preventive-vaccine-development>.
63. Joyce A. Martin, et al. "Births in the United States, 2023." *National Center for Health Statistics*, Aug. 2024. <https://www.cdc.gov/nchs/products/databriefs/db507.htm>.
64. "Vaccine Injury Compensation Program." *Civil Division U.S. Department of Justice*, Jan. 25, 2023. <https://www.justice.gov/civil/vicp>.
65. "Clinical Overview of Rotavirus." *Centers for Disease Control and Prevention*, Apr. 2, 2024. <https://www.cdc.gov/rotavirus/hcp/clinical-overview/index.html>.
66. April Kilgore, et al. "Rotavirus-associated Hospitalization and Emergency Department Costs and Rotavirus Vaccine Program Impact." *Vaccine*, Jul. 8, 2013, Vol. 31(38): 4164-4171. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652939/>.
67. Mondher Toumi and Walter Ricciardi. "The Economic Value of Vaccination: Why Prevention is Wealth." *J Mark Access Health Policy*, Aug. 12, 2015. Vol. 3:10.3402. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4802700/>.
68. Centers for Disease Control and Prevention. "Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States Through Universal Childhood Vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP)." *MMWR Recomm Rep*. Nov. 22, 1991. Vol. 40(RR-13):1-25. <https://pubmed.ncbi.nlm.nih.gov/1835756/>.
69. "Hepatitis B Basics." U.S. Department of Health and Human Services, Mar. 31, 2023. <https://www.hhs.gov/hepatitis/learn-about-viral-hepatitis/hepatitis-b-basics/index.html>.
70. Sarah Schillie, Claudia Vellozzi, Arthur Reingold, et al. "Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices." *MMWR Recomm Rep*, Jan. 12, 2018, Vol. 67(1):1-31. <https://pubmed.ncbi.nlm.nih.gov/29939980/>.
71. "Hepatitis: Preventing Mother-to-Child Transmission of the Hepatitis B Virus." *World Health Organization*, Jul. 27, 2020. <https://www.who.int/news-room/questions-and-answers/item/hepatitis-preventing-mother-to-child-transmission-of-the-hepatitis-b-virus>.
72. "Hepatitis B." *World Health Organization*, Jul. 23, 2025. <https://www.who.int/news-room/fact-sheets/detail/hepatitis-b>.
73. T Jake Liang. "Hepatitis B: the virus and disease." *Hepatology*, May 2009, Vol. 49(5 Suppl):S13-S21. <https://pubmed.ncbi.nlm.nih.gov/19399811/>.
74. Karen H. Seal, et al. "Risk of Hepatitis B Infection Among Young Injection Drug Users in San Francisco: Opportunities for Intervention." *West J Med*, Jan. 2000. Vol. 172(1):16-20. <https://pmc.ncbi.nlm.nih.gov/articles/PMC1070710/>.
75. Centers for Disease Control and Prevention. "Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States Through Universal Childhood Vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP)." *MMWR Recomm Rep*, Nov. 22, 1991. Vol. 40(RR-13):1-25. <https://pubmed.ncbi.nlm.nih.gov/1835756/>.
76. Nanthida Phattraprayoon, et al. "Duration of Hepatitis B Vaccine-Induced Protection among Medical Students and Healthcare Workers following Primary Vaccination in Infancy and Rate of Immunity Decline." *Vaccines*, Feb. 8, 2022. Vol. 10(2):267. <https://www.mdpi.com/2076-393X/10/2/267>.
77. U.S. Hepatitis B Vaccine Market Size, Share & Industry Analysis, By Type (Single Antigen and Combination), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others), and Country

- Forecast, 2024-2032." *Fortune Business Insights*, Jul. 7, 2025. <https://www.fortunebusinessinsights.com/u-s-hepatitis-b-vaccine-market-108637>.
78. Sarah Schillie, Claudia Vellozzi, Arthur Reingold, et al. "Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices." *MMWR Recomm Rep*, Jan. 12, 2018, Vol. 67(1):1-31. <https://pubmed.ncbi.nlm.nih.gov/29939980/>.
 79. Penina Haber, Pedro L Moro, Carmen Ng, Paige W Lewis, Beth Hibbs, Sarah F Schillie, Noele P Nelson, Rongxia Li, Brock Stewart, Mariva V Cano. "Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015." *Vaccine*, Jan. 25, 2018, Vol. 36(4):559-564. <https://pubmed.ncbi.nlm.nih.gov/29241647/>.
 80. Health Resources & Services Administration. "National Vaccine Injury Compensation Programs." *Monthly Statistics Report*, Jun. 1, 2025. https://www.hrsa.gov/sites/default/files/hrsa/vicp/vicp-stats-06-01-25.pdf?utm_source=chatgpt.com.
 81. Joyce A. Martin, Bradly E. Hamilton, and Michelle J.K. Osterman. "Births in the United States, 2023." *National Center for Health Statistics Data Brief*, Aug. 2024, No. 507. https://www.cdc.gov/nchs/products/databriefs/db507.htm?utm_source=chatgpt.com.
 82. DP Culhane, E Gollub, R Kuhn, and M Shpaner. "The co-occurrence of AIDS and homelessness: results from the integration of administrative databases for AIDS surveillance and public shelter utilisation in Philadelphia." *J Epidemiol Community Health*, Jul. 2001, Vol. 55(7):515-20. <https://pubmed.ncbi.nlm.nih.gov/11413184/>.
 83. Matthew Fisher, et al. "Implementing Universal and Targeted Policies for Health Equity: Lessons from Australia." *Int J Health Policy Manag*, Nov. 9, 2021. Vol.11(10):2308-2318. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808267/>.
 84. Vaccine Education Center. "Vaccine History: Developments by Year." *Children's Hospital of Philadelphia*, accessed Jul. 23, 2025. <https://www.chop.edu/vaccine-education-center/science-history/vaccine-history/developments-by-year>.
 85. Alaya Koneru, et al. "Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices." *Public Health Rep*, Apr. 3, 2019. Vol. 134(3):255-263. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6505332/>.
 86. Joanne Neale, et al. "Barriers to Accessing Generic Health and Social Care Services: A Qualitative Study of Injecting Drug Users." *Health Soc Care Community*, Mar. 2008. Vol. 16(2):147-54. <https://pubmed.ncbi.nlm.nih.gov/18290980/>.
 87. D. S. Feldman. "Effects of Managed Care on Physician-patient Relationships, Quality of Care, and the Ethical Practice of Medicine: A Physician Survey." *Arch Intern Med*, Aug. 1998. Vol. 158(15):1626-32. <https://pubmed.ncbi.nlm.nih.gov/9701096/>.
 88. "HEDIS Measures & Billing Codes." *Health Net*, accessed Jul. 23, 2025. https://www.healthnet.com/content/healthnet/en_us/providers/working-with-hn/hedis-measure-specifications.html.
 89. Jim Atherton. "Development of the Electronic Health Record." *AMA Journal of Ethics*, Mar. 2011. Vol. 13(3):86-190. <https://journalofethics.ama-assn.org/article/development-electronic-health-record/2011-03>.
 90. Clemens Kruse. "The Use of Electronic Health Records to Support Population Health: A Systematic Review of the Literature." *Journal of Medical Systems*, Sept. 29, 2018. Vol. 42(11):214. <https://link.springer.com/article/10.1007/s10916-018-1075-6>.
 91. Mitchell H Katz (2020). "The Public Health Response to HIV/AIDS: What Have We Learned?" *The AIDS Pandemic*, May 9, 2007, Vol. 9:90-109. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148643/>.
 92. "Looking Back: The AIDS Epidemic." *SF LGBT Center*, Dec. 15, 2018. <https://www.sfcenter.org/history/looking-back-the-aids-epidemic/>.
 93. Matthew Fisher, et al. "Implementing universal and targeted policies for health equity: Lessons from Australia." *Int J Health Policy Manag*, Nov. 9, 2021. Vol. 11(10):2308-2318. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808267/>.

94. Valarie Blake. "The National Childhood Vaccine Injury Act and the Supreme Court's Interpretation." *AMA J. Ethics*, Jan. 2012. Vol. 14(1):31-34. <https://journalofethics.ama-assn.org/article/national-childhood-vaccine-injury-act-and-supreme-courts-interpretation/2012-01>.
95. Institute of Medicine (US) Committee on the Children's Vaccine Initiative: Planning Alternative Strategies. "The Children's Vaccine Initiative: Achieving the Vision." *National Academies Press*, 1993. <https://www.ncbi.nlm.nih.gov/books/NBK236419/>.
96. Richard Goldberg. "Vaccine Liability in the Light of Covid-19: A Defence of Risk-Benefit." *Medical Law Review*, Spring 2022. Vol. 30(2):243-271. <https://academic.oup.com/medlaw/article/30/2/243/6506562>.
97. "National Vaccine Injury Compensation Program." *Health Resources and Services Administration*, accessed Jul. 10, 2025. <https://www.hrsa.gov/vaccine-compensation>.
98. "Liability and Adverse Event Reporting (VAERS)." *American College of Obstetricians and Gynecologists*, accessed Jul. 10, 2025. <https://www.acog.org/education-and-events/publications/liability-and-adverse-event-reporting-vaers>.
99. The College of Physicians of Philadelphia. "Vaccine Injury Compensation Programs." *History of Vaccines*, accessed Jul. 10, 2025. <https://historyofvaccines.org/content/articles/vaccine-injury-compensation-programs>.
100. The College of Physicians of Philadelphia. "The Development of the Immunization Schedule." *History of Vaccines*, accessed Jul. 8, 2025. <https://historyofvaccines.org/getting-vaccinated/vaccines-children/development-immunization-schedule/>.
101. "Measles, Mumps, and Rubella Vaccines." *The Smithsonian Institution*, accessed Jul. 10, 2025. <https://www.si.edu/spotlight/antibody-initiative/mmr>.
102. Frank DeStefano and Tom T Shimabukuro. "The MMR Vaccine and Autism." *Annu Rev of Virol.*, Apr. 15, 2019, Vol. 6(1):585-600. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6768751/>.
103. Joint News Release. "Nearly 40 million children are dangerously susceptible to growing measles threat." *World Health Organization*, Nov. 23, 2022. <https://www.who.int/news/item/23-11-2022-nearly-40-million-children-are-dangerously-susceptible-to-growing-measles-threat>.
104. Paolo Bellavite. "Causality assessment of adverse events following immunization: the problem of multifactorial pathology." *F1000Res.*, Apr. 14, 2020, Vol. 9:170. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7111503/>.
105. "Liability and Adverse Event Reporting (VAERS)." *American College of Obstetricians and Gynecologists*, accessed Jul. 10, 2025. <https://www.acog.org/education-and-events/publications/liability-and-adverse-event-reporting-vaers>.
106. Ross Lazarus. "Electronic Support for Public Health - Vaccine Adverse Event Reporting System (ESP:VAERS) - Final Report." *Agency for Healthcare Research and Quality*, accessed Jul 10, 2025. <https://digital.ahrq.gov/ahrq-funded-projects/electronic-support-public-health-vaccine-adverse-event-reporting-system>.
107. Vaccine Education Center. "Rotavirus: The Disease & Vaccines." *Children's Hospital of Philadelphia*, accessed Jul. 10, 2025. <https://www.chop.edu/vaccine-education-center/vaccine-details/rotavirus-vaccine>.
108. "America's Children: Key National Indicators of Well-Being, 2023 - Demographic Background." *Federal Interagency Forum on Child and Family Statistics*, accessed Jul. 21, 2025. <https://www.childstats.gov/americaschildren23/demo.asp>.
109. Lakshmi Sukumaran, Natalie L. McCarthy, Rongxia Li, Eric Weintraub, et al. "Demographic characteristics of members of the Vaccine Safety Datalink (VSD): A comparison with the United States population." *Vaccine*, Jul. 23, 2015, Vol. 33(36):4446-4450. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547875/>.
110. Megan G Hofmeister, Shaoman Yin, Noele P Nelson, Mark K Weng, Neil Gupta. "Trends and Opportunities: Hepatitis A Virus Infection, Seroprevalence, and Vaccination Coverage-United States, 1976-2020." *Public Health Rep.* Jul. 2023, Vol. 21:333549231184007. <https://pubmed.ncbi.nlm.nih.gov/37480244/>.
111. Megan G. Hofmeister and Neil Gupta. "Preventable Deaths During Widespread Community Hepatitis A Outbreaks – United States, 2016-2022." *Morbidity and Mortality Weekly Report*, Oct. 20, 2023, Vol. 72(42):1135-1142. <https://www.cdc.gov/mmwr/volumes/72/wr/mm7242a1.htm>.

112. Noele P. Nelson, Mark K. Weng, Megan G. Hofmeister, et al. "Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020." *Morbidity and Mortality Weekly Report*, Jul. 3, 2020, Vol. 69(5):1-38. <https://www.cdc.gov/mmwr/volumes/69/rr/rr6905a1.htm>.
113. The College of Physicians of Philadelphia. "Hepatitis A and Hepatitis B." *History of Vaccines*, updated Jul. 2025. <https://historyofvaccines.org/diseases/hepatitis-and-hepatitis-b/>.
114. Monique A. Foster, Megan G. Hofmeister, Shaoman Yin, et al. "Widespread Hepatitis A Outbreaks Associated with Person-to-Person Transmission – United States, 2016–2020." *Morbidity and Mortality Weekly Report*, Sept. 30, 2022, Vol. 71(39):1229-1234. <https://www.cdc.gov/mmwr/volumes/71/wr/mm7139a1.htm>.
115. Alberto Giubulini. "Vaccination ethics." *British Medical Bulletin*, Mar. 2021, Vol. 137(1):4-12. <https://academic.oup.com/bmb/article/137/1/4/6047735>.
116. "Hepatitis: Preventing mother-to-child transmission of the hepatitis B virus." *World Health Organization*, Jul. 27, 2020. <https://www.who.int/news-room/questions-and-answers/item/hepatitis-preventing-mother-to-child-transmission-of-the-hepatitis-b-virus>.
117. Karen H Seal, Brian R Edlin, Kristen C Ochoa, Jacqueline P Tulskey, Andrew R Moss, and Judith A Hahn. "Risk of hepatitis B infection among young injection drug users in San Francisco: opportunities for intervention." *West J Med.*, Jan. 2000, Vol. 95(1):16-20. <https://pmc.ncbi.nlm.nih.gov/articles/PMC1070710/>.
118. Lucija Tomljenovic, and Christopher A Shaw. "Do aluminum vaccine adjuvants contribute to the rising prevalence of autism?" *J Inorg Biochem.*, Nov. 2011, Vol. 105(11):1489-99. <https://pubmed.ncbi.nlm.nih.gov/22099159/>.
119. World Health Organization. "Aluminium adjuvants." *WHO Weekly Epidemiological Record*, Jul. 27, 2012 <https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/adjuvants>.
120. Kreesten M Madsen, Marlene B Lauritsen, Carsten B Pedersen, et al. "Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data." *Pediatrics*, Sept. 2022, Vol. 112(3 Pt 1): 604-6. <https://pubmed.ncbi.nlm.nih.gov/12949291/>.
121. Institute of Medicine. *The Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence, and Future Studies*. Washington, DC: National Academies Press, 2013. <https://nap.nationalacademies.org/catalog/13563/the-childhood-immunization-schedule-and-safety-stakeholder-concerns-scientific-evidence>.
122. James Lyons-Weiler, and Robert Ricketson. "Reconsideration of the immunotherapeutic pediatric safe dose levels of aluminum." *J. Trace Elem. Med. Biol.*, Jul. 2018, Vol. 48:67-73. <https://www.sciencedirect.com/science/article/pii/S0946672X17300950>.
123. Robert J. Mitkus, David B. King, Maureen A. Hess, Richard A. Forshee, and Mark O. Walderhaug. "Updated aluminum pharmacokinetics following infant exposures through diet and vaccination." *Vaccine*, Nov. 28, 2011. Vol. 29(51), 9538-9543. <https://www.sciencedirect.com/science/article/abs/pii/S0264410X11015799>.
124. Matthew F Daley, Liza M Reifler, Jason M Glanz, et al. "Association Between Aluminum Exposure From Vaccines Before Age 24 Months and Persistent Asthma at Age 24 to 59 Months." *Acad Pediatr.*, Sept. 28, 2022, Vol. 23(1):37-46. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10109516/>.
125. Niklas Worm Andersson, Ingrid Bech Svalgaard, Stine Skovbo Hoffmann, and Anders Hviid. "Aluminum-Adsorbed Vaccines and Chronic Diseases in Childhood: A Nationwide Cohort Study." *Ann Intern Med.*, July 15, 2025. <https://pubmed.ncbi.nlm.nih.gov/40658954/>.
126. Ibid.
127. Ibid.
128. "Childhood vaccination programme." *Statens Serum Institut*, Aug. 20, 2019. <https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme>.
129. Rane Seither, Oyindamola Bidemi Yusuf, Devon Dramann, Kayla Calhoun, Agnes Mugerwa-Kasujja, Cynthia L. Knighton, Jennifer L. Kriss, Rebecca Miller, Georgina Peacock. "Coverage with selected vaccines and exemption rates among children in kindergarten – United States, 2023–24 school year." *Morbidity and Mortality Weekly Report*, Oct. 17, 2024. Vol. 73(41), 925-932. <https://www.cdc.gov/mmwr/volumes/73/wr/mm7341a3.htm>.

130. Cheprha McKee and Kristin Bohannon. "Exploring the reasons behind parental refusal of vaccines." *J Pediatr Pharmacol Ther.*, Mar.-Apr. 2016, Vol. 21(2), 104-109. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4869767/>; Cary Funk, Alec Tyson, Brian Kennedy, and Giancarlo Pasquini. "Americans' largely positive views of childhood vaccines hold steady." *Pew Research Center*, May 16, 2023. <https://www.pewresearch.org/science/2023/05/16/americans-largely-positive-views-of-childhood-vaccines-hold-steady/>.
131. Pedro Plans-Rubió. "Evaluation of the Establishment of Herd Immunity in the Population by Means of Serological Surveys and Vaccination Coverage." *Hum Vaccin Immunother*, Feb. 2012. Vol. 8(2):184-8. <https://pubmed.ncbi.nlm.nih.gov/22426372/>.
132. "What is the history of Rubella vaccine in America?" *National Vaccine Information Center*, Feb. 18, 2023. <https://www.nvic.org/disease-vaccine/rubella/vaccine-history>; "Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry." *U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research*, Oct. 2023. <https://www.fda.gov/media/139638/download>; "Principles and considerations for adding a vaccine to a national immunization programme: from decision to implementation and monitoring." *World Health Organization*, 2014. <https://apps.who.int/iris/handle/10665/111548>; Institute of Medicine. *The Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence, and Future Studies*. Washington, DC: National Academies Press, 2013. <https://nap.nationalacademies.org/catalog/13563/the-childhood-immunization-schedule-and-safety-stakeholder-concerns-scientific-evidence>.

The information provided in this paper is for educational and informational purposes only and is not intended as medical advice.

